This project focuses on Analysis 2 of the Study Protocol, which aims to characterize pregnant individuals with OUD and examine hazards of maternal death and overdose. A poster was presented at Academy Health annual research meeting focusing on analysis on those with OUD and at least one day of MOUD prescription. (Section 7)
Data Source
Inclusion Criteria
Statistical analysis
Descriptive statistics were computed using frequencies (proportions) and medians (IQRs) as appropriate for the overall sample and also stratified by timing of MOUD receipt. Timing of MOUD receipt variable was categorized relative to timing of delivery and has two levels: receipt during one period only either pre- or post-delivery or receipt during both pre- and post-delivery periods. Due to the low number of outcomes, several variables were collapsed into one. These variables are listed below.
Total days of MOUD receipt was calculated using three different methods. Method 1 sums the days supply variable (“daysup”) and if the pre-delivery period number is greater than 90 days, then it is capped at 90. Similarly, this method caps the post-delivery days supply to 42. Numerical example:
studyid from_day daysup total.rx.days
96 002007060499-05446655-02100650 -106 14 14
97 002007060499-05446655-02100650 -106 14 28
98 002007060499-05446655-02100650 -105 14 42
99 002007060499-05446655-02100650 -94 30 72
100 002007060499-05446655-02100650 -93 30 90
101 002007060499-05446655-02100650 -64 1 90
102 002007060499-05446655-02100650 -63 30 90
Pre-delivery days of MOUD is calculated as 90 for this individual.
Method 2 also sums the days supply variable, but the number of days over 90 is added to the post-delivery period. Method 2 caps the pre-delivery days to 90 and the post delivery days to 42. Numerical example below:
studyid from_day daysup total.rx.days
96 002007060499-05446655-02100650 -106 14 14
97 002007060499-05446655-02100650 -106 14 28
98 002007060499-05446655-02100650 -105 14 42
99 002007060499-05446655-02100650 -94 30 72
100 002007060499-05446655-02100650 -93 30 102
101 002007060499-05446655-02100650 -64 1 103
102 002007060499-05446655-02100650 -63 30 133
Pre-delivery days of MOUD is calculated as 90 for this individual, and the additional 43 days are carried over to the post-delivery period. However, the post-delivery days supply is capped to 42.
Method 3 was used in the conference abstract, as it was the most conservative approach. This method counts for overlapping prescription dates using the “from_day” variable, which is the number of days anchored from Day 42 of the exposure period (e.g. from_day -132 is the first day of the exposure period), and sums the number of days covered. Days supply greater than 90 in the pre-period is carried onto the post-delivery period but overlapping prescription dates are not counted. Numerical example below:
studyid daysup from_day
96 002007060499-05446655-02100650 14 -106
97 002007060499-05446655-02100650 14 -106
98 002007060499-05446655-02100650 14 -105
99 002007060499-05446655-02100650 30 -94
100 002007060499-05446655-02100650 30 -93
101 002007060499-05446655-02100650 1 -64
102 002007060499-05446655-02100650 30 -63
studyid pre_days_covered carryover_days
17 002007060499-05446655-02100650 64 9
For this individual, 64 days are counted starting from Day -106 to -43 days and 9 carryover days are counted into the post-delivery period.
After calculating the number of days of MOUD receipt, various histograms were plotted to examine differences by method. Then, multivariable Cox Proportional hazards model were used to determine the associations between total days of MOUD receipt as the main exposure and death or overdose as the outcome. For individuals with multiple outcomes, the earliest outcome was used. Outcomes that occurred during the follow-up period were counted if they were captured in the TN all payer database if an individual lost eligibility for TennCare. Average dose per day of MOUD receipt (qty*dose)/(days supply) was also calculated and described in the table. Average days supply and dose from the pre-delivery period that exceeded 90 days was carried over and added to the post-delivery period.
The Cox model was first modeled using linear continuous terms, due to the limited degrees of freedom. However, year of delivery was determined to be non-linear and was modeled using a restricted cubic spline with 3 knots. These models included the following covariates: year of delivery, total day MOUD receipt, age at delivery, gestation weeks, route of delivery, combined pain conditions, alcohol/other substance use, benzodiazepine/anticonvulsant use, anxiety/depression, maternal morbidity (CDC defined). Additional covariates were included initially but were removed due to the small number of outcomes. These include race/ethnicity combined, number of previous pregnancies, schizophrenia/personality disorder, CDC social vulnerability index, and timing of MOUD receipt (one or two periods relative to delivery). Robust standard errors clustered at the individual level were computed.
Future analyses planned: + Repeat analysis excluding those who received naltrexone and methadone + Include individuals with the exposure period starting at 180 days before delivery + Include individuals with up to 30-days gap in enrollment
Additonal notes: few outcomes (<5) prior to 2015
| N | No MOUD | MOUD | Test Statistic | |
|---|---|---|---|---|
| (N=7631) | (N=7472) | |||
| Year of delivery | 15103 (100.00) | F1,15101=1238.74, P<0.00013 | ||
| Median (interquartile range) | 2014 (2011—2017) | 2016 (2014—2018) | ||
| Range | 2007—2020 | 2007—2020 | ||
| Age at delivery | 15103 (100.00) | F1,15101=79.02, P<0.00013 | ||
| Median (interquartile range) | 27 (23—30) | 27 (24—31) | ||
| Range | 15—44 | 17—44 | ||
| Number of Gestation weeks | 15103 (100.00) | F1,15101=97.93, P<0.00013 | ||
| Median (interquartile range) | 38 (37—39) | 39 (37—39) | ||
| Range | 22—43 | 21—42 | ||
| Race | 15099 (99.97) |
Χ2 4=212.83, P<0.00012 |
||
| American Indian or Alaska Native | 21/7627 (0.28) | 23/7472 (0.31) | ||
| Asian or Pacific Islander | 14/7627 (0.18) | 11/7472 (0.15) | ||
| Black of African American | 617/7627 (8.09) | 210/7472 (2.81) | ||
| Other or Unknown | 86/7627 (1.13) | 53/7472 (0.71) | ||
| White | 6889/7627 (90.32) | 7175/7472 (96.03) | ||
| Hispanic : Not Hispanic | 15089 (99.91) | 7534/7624 (98.82) | 7398/7465 (99.10) |
Χ2 1=2.93, P=0.08682 |
| Race/Ethnicity combined | 15103 (100.00) |
Χ2 4=209.22, P<0.00012 |
||
| Hispanic | 90/7631 (1.18) | 67/7472 (0.90) | ||
| Non-Hispanic Asian | 13/7631 (0.17) | 11/7472 (0.15) | ||
| Non-Hispanic Black | 613/7631 (8.03) | 209/7472 (2.80) | ||
| Non-Hispanic Other | 74/7631 (0.97) | 55/7472 (0.74) | ||
| Non-Hispanic White | 6841/7631 (89.65) | 7130/7472 (95.42) | ||
| Route of delivery : Vaginal | 15103 (100.00) | 4966/7631 (65.08) | 4857/7472 (65.00) |
Χ2 1=0.01, P=0.92412 |
| Number of previous pregnancies | 14869 (98.45) | F1,14867=6.63, P=0.01003 | ||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—24 | 0—23 | ||
| Final outcome | 15103 (100.00) |
Χ2 3=411.87, P<0.00012 |
||
| Death | 47/7631 (0.62) | 30/7472 (0.40) | ||
| Overdose | 84/7631 (1.10) | 97/7472 (1.30) | ||
| Loss of enrollment | 1629/7631 (21.35) | 709/7472 (9.49) | ||
| Censored | 5871/7631 (76.94) | 6636/7472 (88.81) | ||
| Final outcome (w/o all payer data) | 15103 (100.00) |
Χ2 3=409.14, P<0.00012 |
||
| Death | 19/7631 (0.25) | 11/7472 (0.15) | ||
| Overdose | 77/7631 (1.01) | 91/7472 (1.22) | ||
| Loss of enrollment | 1664/7631 (21.81) | 734/7472 (9.82) | ||
| Censored | 5871/7631 (76.94) | 6636/7472 (88.81) | ||
| Total days supplied MOUD | 15103 (100.00) | F1,15101=93419.74, P<0.00013 | ||
| Median (interquartile range) | 0 (0—0) | 96 (56—120) | ||
| Range | 0—112 | 1—132 | ||
| Total days supplied MOUD before delivery | 15103 (100.00) | F1,15101=46301.24, P<0.00013 | ||
| Median (interquartile range) | 0 (0—0) | 74 (35—90) | ||
| Range | 0—84 | 0—90 | ||
| Total days supplied MOUD after delivery | 15103 (100.00) | F1,15101=24424.08, P<0.00013 | ||
| Median (interquartile range) | 0 (0—0) | 30 (9—42) | ||
| Range | 0—28 | 0—42 | ||
| Total days supplied MOUD (method 2) | 15103 (100.00) | F1,15101=93814.73, P<0.00013 | ||
| Median (interquartile range) | 0 (0—0) | 98 (56—125) | ||
| Range | 0—112 | 1—132 | ||
| Total days supplied MOUD before delivery (method 2) | 15103 (100.00) | F1,15101=46301.24, P<0.00013 | ||
| Median (interquartile range) | 0 (0—0) | 74 (35—90) | ||
| Range | 0—84 | 0—90 | ||
| Total days supplied MOUD after delivery (method 2) | 15103 (100.00) | F1,15101=27941.69, P<0.00013 | ||
| Median (interquartile range) | 0 (0—0) | 30 (14—42) | ||
| Range | 0—28 | 0—42 | ||
| Total days supplied MOUD (method 3) | 7472 (49.47) | |||
| Median (interquartile range) | — | 89 (47—112) | ||
| Range | — | 1—132 | ||
| Total days supplied MOUD before delivery (method 3) | 7472 (49.47) | |||
| Median (interquartile range) | — | 62 (30—78) | ||
| Range | — | 0—90 | ||
| Total days supplied MOUD after delivery (method 3) | 7472 (49.47) | |||
| Median (interquartile range) | — | 30 (13—40) | ||
| Range | — | 0—42 | ||
| Avg dose pre-delivery (mg) | 7394 (48.96) | |||
| Median (interquartile range) | — | 14.24 (8.00—16.00) | ||
| Range | — | 0.00—50.00 | ||
| Avg dose post-delivery (mg) | 7394 (48.96) | |||
| Median (interquartile range) | — | 9.72 (4.00—16.00) | ||
| Range | — | 0.00—53.57 | ||
| Avg dose exposure (mg) | 7394 (48.96) | |||
| Median (interquartile range) | — | 14.09 (9.42—16.00) | ||
| Range | — | 0.14—53.57 | ||
| Total days buprenorphine before delivery (method 3) | 7299 (48.33) | |||
| Median (interquartile range) | — | 63.00 (30.00—78.00) | ||
| Range | — | 0.00—90.00 | ||
| Total days buprenorphine after delivery (method 3) | 7299 (48.33) | |||
| Median (interquartile range) | — | 30.00 (13.00—41.00) | ||
| Range | — | 0.00—42.00 | ||
| Total days supplied buprenorphine | 7299 (48.33) | |||
| Median (interquartile range) | — | 90.00 (49.00—112.00) | ||
| Range | — | 1.00—132.00 | ||
| Avg dose BUP pre-delivery (mg) | 7298 (48.32) | |||
| Median (interquartile range) | — | 14.12 (8.00—16.00) | ||
| Range | — | 0.00—35.42 | ||
| Avg dose BUP post-delivery (mg) | 7298 (48.32) | |||
| Median (interquartile range) | — | 9.71 (4.00—16.00) | ||
| Range | — | 0.00—42.67 | ||
| Avg dose BUP exposure (mg) | 7298 (48.32) | |||
| Median (interquartile range) | — | 13.98 (9.13—16.00) | ||
| Range | — | 0.14—42.67 | ||
| Combined pain : Yes | 15103 (100.00) | 6000/7631 (78.63) | 5766/7472 (77.17) |
Χ2 1=4.67, P=0.03082 |
| Schizophrenia or personality disorder : Yes | 15103 (100.00) | 598/7631 (7.84) | 583/7472 (7.80) |
Χ2 1=0.01, P=0.93802 |
| Alcohol or other substance use : Yes | 15103 (100.00) | 4490/7631 (58.84) | 3342/7472 (44.73) |
Χ2 1=301.15, P<0.00012 |
| Benzodiazepine or anticonvulsant use : Yes | 15103 (100.00) | 996/7631 (13.05) | 1077/7472 (14.41) |
Χ2 1=5.91, P=0.01502 |
| Maternal morbidity : Yes | 15103 (100.00) | 776/7631 (10.17) | 528/7472 (7.07) |
Χ2 1=46.07, P<0.00012 |
| Anxiety and depression combined : Yes | 15103 (100.00) | 2987/7631 (39.14) | 3485/7472 (46.64) |
Χ2 1=86.67, P<0.00012 |
| Back pain : Yes | 15103 (100.00) | 3189/7631 (41.79) | 2528/7472 (33.83) |
Χ2 1=101.61, P<0.00012 |
| Depression : Yes | 15103 (100.00) | 2587/7631 (33.90) | 2946/7472 (39.43) |
Χ2 1=49.66, P<0.00012 |
| Bipolar disorder : Yes | 15103 (100.00) | 830/7631 (10.88) | 819/7472 (10.96) |
Χ2 1=0.03, P=0.86822 |
| Other substance use : Yes | 15103 (100.00) | 4363/7631 (57.17) | 3197/7472 (42.79) |
Χ2 1=312.63, P<0.00012 |
| Tobacco use : Yes | 15103 (100.00) | 5201/7631 (68.16) | 5196/7472 (69.54) |
Χ2 1=3.37, P=0.06652 |
| Med NSAIDS : Yes | 15103 (100.00) | 4754/7631 (62.30) | 4602/7472 (61.59) |
Χ2 1=0.80, P=0.36992 |
| Schizophrenia psychotic disorders : Yes | 15103 (100.00) | 398/7631 (5.22) | 466/7472 (6.24) |
Χ2 1=7.30, P=0.00692 |
| Anxiety : Yes | 15103 (100.00) | 1113/7631 (14.59) | 1608/7472 (21.52) |
Χ2 1=122.93, P<0.00012 |
| Med benzodiazepine use : Yes | 15103 (100.00) | 660/7631 (8.65) | 713/7472 (9.54) |
Χ2 1=3.65, P=0.05622 |
| Maternal morbidity : Yes | 15103 (100.00) | 776/7631 (10.17) | 528/7472 (7.07) |
Χ2 1=46.07, P<0.00012 |
| Dental pain : Yes | 15103 (100.00) | 410/7631 (5.37) | 298/7472 (3.99) |
Χ2 1=16.20, P=0.00012 |
| Alcohol use disorder : Yes | 15103 (100.00) | 502/7631 (6.58) | 507/7472 (6.79) |
Χ2 1=0.26, P=0.61062 |
| Med anticonvulsant use : Yes | 15103 (100.00) | 423/7631 (5.54) | 432/7472 (5.78) |
Χ2 1=0.40, P=0.52622 |
| Med muscle relaxant use : Yes | 15103 (100.00) | 649/7631 (8.50) | 371/7472 (4.97) |
Χ2 1=75.11, P<0.00012 |
| Personality disorder : Yes | 15103 (100.00) | 283/7631 (3.71) | 220/7472 (2.94) |
Χ2 1=6.85, P=0.00892 |
| Fibromyalgia : Yes | 15103 (100.00) | 555/7631 (7.27) | 383/7472 (5.13) |
Χ2 1=29.88, P<0.00012 |
| CDC SVI overall percentile ranking of all 4 themes | 14003 (92.72) | F1,14001=18.02, P<0.00013 | ||
| Median (interquartile range) | 0.60 (0.38—0.81) | 0.58 (0.37—0.79) | ||
| Range | 0.00—1.00 | 0.00—1.00 |
| N | No MOUD | Only pre | Only post | Both pre and post | |
|---|---|---|---|---|---|
| (N=7631) | (N=898) | (N=638) | (N=5936) | ||
| Year of delivery | 15103 (100.00) | ||||
| Median (interquartile range) | 2014 (2011—2017) | 2016 (2015—2018) | 2016 (2014—2019) | 2016 (2014—2018) | |
| Range | 2007—2020 | 2007—2020 | 2007—2020 | 2007—2020 | |
| Year of delivery as categorical | 15103 (100.00) | ||||
| 2007 | 284/7631 (3.72) | 1/898 (0.11) | 6/638 (0.94) | 25/5936 (0.42) | |
| 2008 | 312/7631 (4.09) | 3/898 (0.33) | 15/638 (2.35) | 41/5936 (0.69) | |
| 2009 | 467/7631 (6.12) | 10/898 (1.11) | 19/638 (2.98) | 52/5936 (0.88) | |
| 2010 | 478/7631 (6.26) | 6/898 (0.67) | 24/638 (3.76) | 112/5936 (1.89) | |
| 2011 | 554/7631 (7.26) | 19/898 (2.12) | 27/638 (4.23) | 146/5936 (2.46) | |
| 2012 | 611/7631 (8.01) | 28/898 (3.12) | 19/638 (2.98) | 223/5936 (3.76) | |
| 2013 | 595/7631 (7.80) | 40/898 (4.45) | 43/638 (6.74) | 438/5936 (7.38) | |
| 2014 | 659/7631 (8.64) | 79/898 (8.80) | 48/638 (7.52) | 684/5936 (11.52) | |
| 2015 | 690/7631 (9.04) | 121/898 (13.47) | 60/638 (9.40) | 821/5936 (13.83) | |
| 2016 | 769/7631 (10.08) | 155/898 (17.26) | 61/638 (9.56) | 769/5936 (12.95) | |
| 2017 | 667/7631 (8.74) | 124/898 (13.81) | 70/638 (10.97) | 635/5936 (10.70) | |
| 2018 | 610/7631 (7.99) | 125/898 (13.92) | 58/638 (9.09) | 621/5936 (10.46) | |
| 2019 | 552/7631 (7.23) | 113/898 (12.58) | 91/638 (14.26) | 663/5936 (11.17) | |
| 2020 | 383/7631 (5.02) | 74/898 (8.24) | 97/638 (15.20) | 706/5936 (11.89) | |
| Age at delivery | 15103 (100.00) | ||||
| Median (interquartile range) | 27 (23—30) | 27 (24—31) | 27 (24—31) | 27 (24—31) | |
| Range | 15—44 | 18—43 | 17—44 | 17—44 | |
| Number of Gestation weeks | 15103 (100.00) | ||||
| Median (interquartile range) | 38 (37—39) | 39 (37—39) | 38 (37—39) | 39 (37—39) | |
| Range | 22—43 | 24—42 | 23—42 | 21—42 | |
| Race | 15099 (99.97) | ||||
| American Indian or Alaska Native | 21/7627 (0.28) | 4/898 (0.45) | 3/638 (0.47) | 16/5936 (0.27) | |
| Asian or Pacific Islander | 14/7627 (0.18) | 1/898 (0.11) | 1/638 (0.16) | 9/5936 (0.15) | |
| Black of African American | 617/7627 (8.09) | 35/898 (3.90) | 22/638 (3.45) | 153/5936 (2.58) | |
| Other or Unknown | 86/7627 (1.13) | 11/898 (1.22) | 5/638 (0.78) | 37/5936 (0.62) | |
| White | 6889/7627 (90.32) | 847/898 (94.32) | 607/638 (95.14) | 5721/5936 (96.38) | |
| Hispanic : Not Hispanic | 15089 (99.91) | 7534/7624 (98.82) | 886/895 (98.99) | 633/637 (99.37) | 5879/5933 (99.09) |
| Race/Ethnicity combined | 15103 (100.00) | ||||
| Hispanic | 90/7631 (1.18) | 9/898 (1.00) | 4/638 (0.63) | 54/5936 (0.91) | |
| Non-Hispanic Asian | 13/7631 (0.17) | 1/898 (0.11) | 1/638 (0.16) | 9/5936 (0.15) | |
| Non-Hispanic Black | 613/7631 (8.03) | 34/898 (3.79) | 22/638 (3.45) | 153/5936 (2.58) | |
| Non-Hispanic Other | 74/7631 (0.97) | 13/898 (1.45) | 7/638 (1.10) | 35/5936 (0.59) | |
| Non-Hispanic White | 6841/7631 (89.65) | 841/898 (93.65) | 604/638 (94.67) | 5685/5936 (95.77) | |
| Route of delivery : Vaginal | 15103 (100.00) | 4966/7631 (65.08) | 614/898 (68.37) | 421/638 (65.99) | 3822/5936 (64.39) |
| Number of previous pregnancies | 14869 (98.45) | ||||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | 2 (1—3) | 2 (1—3) | |
| Range | 0—24 | 0—19 | 0—23 | 0—23 | |
| Final outcome | 15103 (100.00) | ||||
| Death | 47/7631 (0.62) | 3/898 (0.33) | 2/638 (0.31) | 25/5936 (0.42) | |
| Overdose | 84/7631 (1.10) | 19/898 (2.12) | 16/638 (2.51) | 62/5936 (1.04) | |
| Loss of enrollment | 1629/7631 (21.35) | 100/898 (11.14) | 90/638 (14.11) | 519/5936 (8.74) | |
| Censored | 5871/7631 (76.94) | 776/898 (86.41) | 530/638 (83.07) | 5330/5936 (89.79) | |
| Total days supplied MOUD | 15103 (100.00) | ||||
| Median (interquartile range) | 0 (0—0) | 30 (15—56) | 28 (14—33) | 108 (84—122) | |
| Range | 0—112 | 1—90 | 1—70 | 7—132 | |
| Total days supplied MOUD before delivery | 15103 (100.00) | ||||
| Median (interquartile range) | 0 (0—0) | 30 (15—56) | 0 (0—0) | 84 (60—90) | |
| Range | 0—84 | 1—90 | 0—28 | 1—90 | |
| Total days supplied MOUD after delivery | 15103 (100.00) | ||||
| Median (interquartile range) | 0 (0—0) | 0 (0—0) | 28 (14—33) | 30 (21—42) | |
| Range | 0—28 | 0—0 | 1—42 | 0—42 | |
| Total days supplied MOUD (method 2) | 15103 (100.00) | ||||
| Median (interquartile range) | 0 (0—0) | 30 (15—56) | 28 (14—33) | 112 (84—129) | |
| Range | 0—112 | 1—132 | 1—70 | 7—132 | |
| Total days supplied MOUD before delivery (method 2) | 15103 (100.00) | ||||
| Median (interquartile range) | 0 (0—0) | 30 (15—56) | 0 (0—0) | 84 (60—90) | |
| Range | 0—84 | 1—90 | 0—28 | 1—90 | |
| Total days supplied MOUD after delivery (method 2) | 15103 (100.00) | ||||
| Median (interquartile range) | 0 (0—0) | 0 (0—0) | 28 (14—33) | 35 (24—42) | |
| Range | 0—28 | 0—42 | 1—42 | 0—42 | |
| Total days supplied MOUD (method 3) | 7472 (49.47) | ||||
| Median (interquartile range) | — | 30 (14—49) | 14 (7—25) | 100 (76—116) | |
| Range | — | 1—89 | 1—41 | 7—132 | |
| Total days supplied MOUD before delivery (method 3) | 7472 (49.47) | ||||
| Median (interquartile range) | — | 30 (14—49) | 0 (0—0) | 69 (48—80) | |
| Range | — | 1—89 | 0—0 | 1—90 | |
| Total days supplied MOUD after delivery (method 3) | 7472 (49.47) | ||||
| Median (interquartile range) | — | 0 (0—0) | 14 (7—25) | 35 (23—41) | |
| Range | — | 0—0 | 1—41 | 1—42 | |
| Avg dose pre-delivery (mg) | 7394 (48.96) | ||||
| Median (interquartile range) | — | 13.90 (8.00—16.00) | 0.00 (0.00—0.00) | 15.00 (9.94—16.00) | |
| Range | — | 0.14—50.00 | 0.00—0.00 | 0.25—50.00 | |
| Avg dose post-delivery (mg) | 7394 (48.96) | ||||
| Median (interquartile range) | — | 0.00 (0.00—0.00) | 15.76 (8.12—16.00) | 12.00 (8.00—16.00) | |
| Range | — | 0.00—0.00 | 0.80—53.57 | 0.00—50.00 | |
| Avg dose exposure (mg) | 7394 (48.96) | ||||
| Median (interquartile range) | — | 13.90 (8.00—16.00) | 15.76 (8.12—16.00) | 14.04 (9.87—16.00) | |
| Range | — | 0.14—50.00 | 0.80—53.57 | 0.25—50.00 | |
| Total days buprenorphine before delivery (method 3) | 7299 (48.33) | ||||
| Median (interquartile range) | — | 30.00 (14.00—49.00) | 0.00 (0.00—0.00) | 69.00 (48.00—80.00) | |
| Range | — | 1.00—89.00 | 0.00—0.00 | 0.00—90.00 | |
| Total days buprenorphine after delivery (method 3) | 7299 (48.33) | ||||
| Median (interquartile range) | — | 0.00 (0.00—0.00) | 14.50 (7.00—25.00) | 35.00 (23.00—41.00) | |
| Range | — | 0.00—0.00 | 1.00—41.00 | 0.00—42.00 | |
| Total days supplied buprenorphine | 7299 (48.33) | ||||
| Median (interquartile range) | — | 30.00 (14.00—49.00) | 14.50 (7.00—25.00) | 100.00 (76.00—116.00) | |
| Range | — | 1.00—89.00 | 1.00—41.00 | 4.00—132.00 | |
| Avg dose BUP pre-delivery (mg) | 7298 (48.32) | ||||
| Median (interquartile range) | — | 13.33 (8.00—16.00) | 0.00 (0.00—0.00) | 14.86 (9.67—16.00) | |
| Range | — | 0.14—29.71 | 0.00—0.00 | 0.00—35.42 | |
| Avg dose BUP post-delivery (mg) | 7298 (48.32) | ||||
| Median (interquartile range) | — | 0.00 (0.00—0.00) | 15.30 (8.00—16.00) | 12.00 (8.00—16.00) | |
| Range | — | 0.00—0.00 | 0.80—42.67 | 0.00—33.24 | |
| Avg dose BUP exposure (mg) | 7298 (48.32) | ||||
| Median (interquartile range) | — | 13.33 (8.00—16.00) | 15.30 (8.00—16.00) | 13.98 (9.75—16.00) | |
| Range | — | 0.14—29.71 | 0.80—42.67 | 0.25—34.47 | |
| Combined pain : Yes | 15103 (100.00) | 6000/7631 (78.63) | 702/898 (78.17) | 473/638 (74.14) | 4591/5936 (77.34) |
| Schizophrenia or personality disorder : Yes | 15103 (100.00) | 598/7631 (7.84) | 83/898 (9.24) | 66/638 (10.34) | 434/5936 (7.31) |
| Alcohol or other substance use : Yes | 15103 (100.00) | 4490/7631 (58.84) | 441/898 (49.11) | 315/638 (49.37) | 2586/5936 (43.56) |
| Benzodiazepine or anticonvulsant use : Yes | 15103 (100.00) | 996/7631 (13.05) | 131/898 (14.59) | 87/638 (13.64) | 859/5936 (14.47) |
| Maternal morbidity : Yes | 15103 (100.00) | 776/7631 (10.17) | 69/898 (7.68) | 52/638 (8.15) | 407/5936 (6.86) |
| Anxiety and depression combined : Yes | 15103 (100.00) | 2987/7631 (39.14) | 403/898 (44.88) | 337/638 (52.82) | 2745/5936 (46.24) |
| Back pain : Yes | 15103 (100.00) | 3189/7631 (41.79) | 308/898 (34.30) | 190/638 (29.78) | 2030/5936 (34.20) |
| Depression : Yes | 15103 (100.00) | 2587/7631 (33.90) | 338/898 (37.64) | 294/638 (46.08) | 2314/5936 (38.98) |
| Bipolar disorder : Yes | 15103 (100.00) | 830/7631 (10.88) | 110/898 (12.25) | 61/638 (9.56) | 648/5936 (10.92) |
| Other substance use : Yes | 15103 (100.00) | 4363/7631 (57.17) | 434/898 (48.33) | 303/638 (47.49) | 2460/5936 (41.44) |
| Tobacco use : Yes | 15103 (100.00) | 5201/7631 (68.16) | 651/898 (72.49) | 428/638 (67.08) | 4117/5936 (69.36) |
| Med NSAIDS : Yes | 15103 (100.00) | 4754/7631 (62.30) | 551/898 (61.36) | 384/638 (60.19) | 3667/5936 (61.78) |
| Schizophrenia psychotic disorders : Yes | 15103 (100.00) | 398/7631 (5.22) | 64/898 (7.13) | 49/638 (7.68) | 353/5936 (5.95) |
| Anxiety : Yes | 15103 (100.00) | 1113/7631 (14.59) | 208/898 (23.16) | 140/638 (21.94) | 1260/5936 (21.23) |
| Med benzodiazepine use : Yes | 15103 (100.00) | 660/7631 (8.65) | 93/898 (10.36) | 56/638 (8.78) | 564/5936 (9.50) |
| Maternal morbidity : Yes | 15103 (100.00) | 776/7631 (10.17) | 69/898 (7.68) | 52/638 (8.15) | 407/5936 (6.86) |
| Dental pain : Yes | 15103 (100.00) | 410/7631 (5.37) | 44/898 (4.90) | 30/638 (4.70) | 224/5936 (3.77) |
| Alcohol use disorder : Yes | 15103 (100.00) | 502/7631 (6.58) | 66/898 (7.35) | 64/638 (10.03) | 377/5936 (6.35) |
| Med anticonvulsant use : Yes | 15103 (100.00) | 423/7631 (5.54) | 48/898 (5.35) | 33/638 (5.17) | 351/5936 (5.91) |
| Med muscle relaxant use : Yes | 15103 (100.00) | 649/7631 (8.50) | 57/898 (6.35) | 50/638 (7.84) | 264/5936 (4.45) |
| Personality disorder : Yes | 15103 (100.00) | 283/7631 (3.71) | 35/898 (3.90) | 31/638 (4.86) | 154/5936 (2.59) |
| Fibromyalgia : Yes | 15103 (100.00) | 555/7631 (7.27) | 55/898 (6.12) | 29/638 (4.55) | 299/5936 (5.04) |
| CDC SVI overall percentile ranking of all 4 themes | 14003 (92.72) | ||||
| Median (interquartile range) | 0.60 (0.38—0.81) | 0.61 (0.38—0.81) | 0.58 (0.37—0.78) | 0.57 (0.36—0.78) | |
| Range | 0.00—1.00 | 0.00—1.00 | 0.00—1.00 | 0.00—1.00 |
Call:
survdiff(formula = Surv(days.to.event, outcome.bin) ~ moud.yes,
data = basic)
N Observed Expected (O-E)^2/E (O-E)^2/V
moud.yes=0 7631 131 130 0.00421 0.00851
moud.yes=1 7472 127 128 0.00430 0.00851
Chisq= 0 on 1 degrees of freedom, p= 0.9
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2000.00 | 2000.00 | 2.0 | 0.380 | 0.100 | 0.180 | 0.580 |
| Hazard Ratio | 2000.00 | 2000.00 | 2.0 | 1.500 | 1.200 | 1.800 | |
| Total days supplied MOUD (method 3) | 1.00 | 31.00 | 30.0 | -0.170 | 0.066 | -0.300 | -0.039 |
| Hazard Ratio | 1.00 | 31.00 | 30.0 | 0.850 | 0.740 | 0.960 | |
| Age at delivery | 27.00 | 31.00 | 4.0 | -0.120 | 0.084 | -0.280 | 0.049 |
| Hazard Ratio | 27.00 | 31.00 | 4.0 | 0.890 | 0.760 | 1.000 | |
| Number of Gestation weeks | 37.00 | 39.00 | 2.0 | -0.094 | 0.072 | -0.230 | 0.048 |
| Hazard Ratio | 37.00 | 39.00 | 2.0 | 0.910 | 0.790 | 1.000 | |
| CDC SVI overall percentile ranking of all 4 themes | 0.25 | 0.75 | 0.5 | -0.240 | 0.190 | -0.620 | 0.140 |
| Hazard Ratio | 0.25 | 0.75 | 0.5 | 0.790 | 0.540 | 1.100 | |
| Number of previous pregnancies | 1.00 | 3.00 | 2.0 | 0.034 | 0.097 | -0.160 | 0.220 |
| Hazard Ratio | 1.00 | 3.00 | 2.0 | 1.000 | 0.860 | 1.300 | |
| Race/Ethnicity binary --- All Other:Non---Hispanic White | 2.00 | 1.00 | 0.700 | 0.310 | 0.093 | 1.300 | |
| Hazard Ratio | 2.00 | 1.00 | 2.000 | 1.100 | 3.700 | ||
| Route of delivery --- Cesarean:Vaginal | 2.00 | 1.00 | 0.014 | 0.200 | -0.380 | 0.410 | |
| Hazard Ratio | 2.00 | 1.00 | 1.000 | 0.690 | 1.500 | ||
| Combined pain --- Yes:No | 1.00 | 2.00 | -0.340 | 0.200 | -0.740 | 0.056 | |
| Hazard Ratio | 1.00 | 2.00 | 0.710 | 0.480 | 1.100 | ||
| Schizophrenia or personality disorder --- Yes:No | 1.00 | 2.00 | 0.340 | 0.260 | -0.180 | 0.860 | |
| Hazard Ratio | 1.00 | 2.00 | 1.400 | 0.840 | 2.400 | ||
| Alcohol or other substance use --- Yes:No | 1.00 | 2.00 | 0.260 | 0.200 | -0.130 | 0.640 | |
| Hazard Ratio | 1.00 | 2.00 | 1.300 | 0.880 | 1.900 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1.00 | 2.00 | 0.170 | 0.240 | -0.310 | 0.640 | |
| Hazard Ratio | 1.00 | 2.00 | 1.200 | 0.730 | 1.900 | ||
| Anxiety --- Yes:No | 1.00 | 2.00 | 0.260 | 0.210 | -0.150 | 0.660 | |
| Hazard Ratio | 1.00 | 2.00 | 1.300 | 0.860 | 1.900 | ||
| Depression --- Yes:No | 1.00 | 2.00 | 0.570 | 0.200 | 0.180 | 0.960 | |
| Hazard Ratio | 1.00 | 2.00 | 1.800 | 1.200 | 2.600 | ||
| Maternal morbidity --- Yes:No | 1.00 | 2.00 | -0.075 | 0.400 | -0.860 | 0.710 | |
| Hazard Ratio | 1.00 | 2.00 | 0.930 | 0.420 | 2.000 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 13.56 | 1 | 0.0002 |
| Total days supplied MOUD (method 3) | 6.47 | 1 | 0.0110 |
| Age at delivery | 1.91 | 1 | 0.1670 |
| Race/Ethnicity binary | 5.12 | 1 | 0.0236 |
| Route of delivery | 0.01 | 1 | 0.9426 |
| Number of Gestation weeks | 1.68 | 1 | 0.1945 |
| Combined pain | 2.84 | 1 | 0.0918 |
| Schizophrenia or personality disorder | 1.67 | 1 | 0.1966 |
| Alcohol or other substance use | 1.74 | 1 | 0.1875 |
| Benzodiazepine or anticonvulsant use | 0.47 | 1 | 0.4942 |
| Anxiety | 1.57 | 1 | 0.2105 |
| Depression | 8.33 | 1 | 0.0039 |
| Maternal morbidity | 0.04 | 1 | 0.8506 |
| CDC SVI overall percentile ranking of all 4 themes | 1.58 | 1 | 0.2092 |
| Number of previous pregnancies | 0.12 | 1 | 0.7252 |
| TOTAL | 80.25 | 15 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016.00 | 2018.00 | 2.0 | 0.47090 | 0.11120 | 0.25290 | 0.68880 |
| Hazard Ratio | 2016.00 | 2018.00 | 2.0 | 1.60100 | 1.28800 | 1.99100 | |
| Total days supplied MOUD (method 3) | 1.00 | 31.00 | 30.0 | 0.01435 | 0.17160 | -0.32200 | 0.35070 |
| Hazard Ratio | 1.00 | 31.00 | 30.0 | 1.01400 | 0.72470 | 1.42000 | |
| Age at delivery | 27.00 | 31.00 | 4.0 | -0.11630 | 0.08410 | -0.28120 | 0.04851 |
| Hazard Ratio | 27.00 | 31.00 | 4.0 | 0.89020 | 0.75490 | 1.05000 | |
| Number of Gestation weeks | 39.00 | 37.00 | -2.0 | 0.09535 | 0.07286 | -0.04745 | 0.23810 |
| Hazard Ratio | 39.00 | 37.00 | -2.0 | 1.10000 | 0.95370 | 1.26900 | |
| CDC SVI overall percentile ranking of all 4 themes | 0.25 | 0.75 | 0.5 | -0.23650 | 0.19350 | -0.61580 | 0.14280 |
| Hazard Ratio | 0.25 | 0.75 | 0.5 | 0.78940 | 0.54020 | 1.15400 | |
| Number of previous pregnancies | 1.00 | 3.00 | 2.0 | 0.03295 | 0.09814 | -0.15940 | 0.22530 |
| Hazard Ratio | 1.00 | 3.00 | 2.0 | 1.03300 | 0.85270 | 1.25300 | |
| Race/Ethnicity binary --- All Other:Non---Hispanic White | 2.00 | 1.00 | 0.68920 | 0.31030 | 0.08100 | 1.29700 | |
| Hazard Ratio | 2.00 | 1.00 | 1.99200 | 1.08400 | 3.66000 | ||
| Route of delivery --- Cesarean:Vaginal | 2.00 | 1.00 | 0.02069 | 0.20030 | -0.37190 | 0.41330 | |
| Hazard Ratio | 2.00 | 1.00 | 1.02100 | 0.68940 | 1.51200 | ||
| Combined pain --- Yes:No | 1.00 | 2.00 | -0.35180 | 0.20420 | -0.75190 | 0.04833 | |
| Hazard Ratio | 1.00 | 2.00 | 0.70340 | 0.47150 | 1.05000 | ||
| Schizophrenia or personality disorder --- Yes:No | 1.00 | 2.00 | 0.31730 | 0.26290 | -0.19800 | 0.83250 | |
| Hazard Ratio | 1.00 | 2.00 | 1.37300 | 0.82040 | 2.29900 | ||
| Alcohol or other substance use --- Yes:No | 1.00 | 2.00 | 0.25230 | 0.19610 | -0.13190 | 0.63660 | |
| Hazard Ratio | 1.00 | 2.00 | 1.28700 | 0.87640 | 1.89000 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1.00 | 2.00 | 0.18050 | 0.24620 | -0.30210 | 0.66320 | |
| Hazard Ratio | 1.00 | 2.00 | 1.19800 | 0.73930 | 1.94100 | ||
| Anxiety --- Yes:No | 1.00 | 2.00 | 0.26620 | 0.20840 | -0.14220 | 0.67460 | |
| Hazard Ratio | 1.00 | 2.00 | 1.30500 | 0.86740 | 1.96300 | ||
| Depression --- Yes:No | 1.00 | 2.00 | 0.56730 | 0.19880 | 0.17780 | 0.95690 | |
| Hazard Ratio | 1.00 | 2.00 | 1.76400 | 1.19500 | 2.60400 | ||
| Maternal morbidity --- Yes:No | 1.00 | 2.00 | -0.08026 | 0.39990 | -0.86400 | 0.70350 | |
| Hazard Ratio | 1.00 | 2.00 | 0.92290 | 0.42150 | 2.02100 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 20.30 | 2 | <0.0001 |
| Nonlinear | 1.58 | 1 | 0.2082 |
| Total days supplied MOUD (method 3) | 6.82 | 2 | 0.0331 |
| Nonlinear | 1.34 | 1 | 0.2472 |
| Age at delivery | 1.92 | 1 | 0.1663 |
| Race/Ethnicity binary | 4.94 | 1 | 0.0262 |
| Route of delivery | 0.01 | 1 | 0.9177 |
| Number of Gestation weeks | 1.72 | 1 | 0.1902 |
| Combined pain | 2.97 | 1 | 0.0849 |
| Schizophrenia or personality disorder | 1.46 | 1 | 0.2269 |
| Alcohol or other substance use | 1.66 | 1 | 0.1979 |
| Benzodiazepine or anticonvulsant use | 0.54 | 1 | 0.4634 |
| Anxiety | 1.63 | 1 | 0.2013 |
| Depression | 8.15 | 1 | 0.0043 |
| Maternal morbidity | 0.04 | 1 | 0.8408 |
| CDC SVI overall percentile ranking of all 4 themes | 1.49 | 1 | 0.2215 |
| Number of previous pregnancies | 0.11 | 1 | 0.7368 |
| TOTAL NONLINEAR | 3.02 | 2 | 0.2207 |
| TOTAL | 90.75 | 17 | <0.0001 |
Call:
glm(formula = outcome.bin ~ moud.yes, family = binomial(link = "logit"),
data = basic, weights = mw$W)
Coefficients:
Estimate Std. Error z value Pr(>|z|)
(Intercept) -3.9566 0.1009 -39.221 <0.0000000000000002 ***
moud.yes -0.2424 0.1508 -1.608 0.108
---
Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
(Dispersion parameter for binomial family taken to be 1)
Null deviance: 1838.6 on 15102 degrees of freedom
Residual deviance: 1836.0 on 15101 degrees of freedom
AIC: 1772.4
Number of Fisher Scoring iterations: 7
OR 2.5 % 97.5 %
(Intercept) 0.01912766 0.01559458 0.02316825
moud.yes 0.78472227 0.58274573 1.05351362
| N | Overall | |
|---|---|---|
| (N=7472) | ||
| Year of delivery | 7472 (100.00) | |
| Median (interquartile range) | 2016 (2014—2018) | |
| Range | 2007—2020 | |
| Age at delivery | 7472 (100.00) | |
| Median (interquartile range) | 27 (24—31) | |
| Range | 17—44 | |
| Number of Gestation weeks | 7472 (100.00) | |
| Median (interquartile range) | 39 (37—39) | |
| Range | 21—42 | |
| Race | 7472 (100.00) | |
| American Indian or Alaska Native | 23/7472 (0.31) | |
| Asian or Pacific Islander | 11/7472 (0.15) | |
| Black of African American | 210/7472 (2.81) | |
| Other or Unknown | 53/7472 (0.71) | |
| White | 7175/7472 (96.03) | |
| Hispanic : Not Hispanic | 7465 (99.91) | 7398/7465 (99.10) |
| Race/Ethnicity combined | 7472 (100.00) | |
| Hispanic | 67/7472 (0.90) | |
| Non-Hispanic Asian | 11/7472 (0.15) | |
| Non-Hispanic Black | 209/7472 (2.80) | |
| Non-Hispanic Other | 55/7472 (0.74) | |
| Non-Hispanic White | 7130/7472 (95.42) | |
| Route of delivery : Vaginal | 7472 (100.00) | 4857/7472 (65.00) |
| Number of previous pregnancies | 7335 (98.17) | |
| Median (interquartile range) | 2 (1—3) | |
| Range | 0—23 | |
| Final outcome | 7472 (100.00) | |
| Death | 30/7472 (0.40) | |
| Overdose | 97/7472 (1.30) | |
| Loss of enrollment | 709/7472 (9.49) | |
| Censored | 6636/7472 (88.81) | |
| Final outcome (w/o all payer data) | 7472 (100.00) | |
| Death | 11/7472 (0.15) | |
| Overdose | 91/7472 (1.22) | |
| Loss of enrollment | 734/7472 (9.82) | |
| Censored | 6636/7472 (88.81) | |
| Total days supplied MOUD | 7472 (100.00) | |
| Median (interquartile range) | 96 (56—120) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery | 7472 (100.00) | |
| Median (interquartile range) | 74 (35—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery | 7472 (100.00) | |
| Median (interquartile range) | 30 (9—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 2) | 7472 (100.00) | |
| Median (interquartile range) | 98 (56—125) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 2) | 7472 (100.00) | |
| Median (interquartile range) | 74 (35—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 2) | 7472 (100.00) | |
| Median (interquartile range) | 30 (14—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 3) | 7472 (100.00) | |
| Median (interquartile range) | 89 (47—112) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 3) | 7472 (100.00) | |
| Median (interquartile range) | 62 (30—78) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 3) | 7472 (100.00) | |
| Median (interquartile range) | 30 (13—40) | |
| Range | 0—42 | |
| Avg dose pre-delivery (mg) | 7394 (98.96) | |
| Median (interquartile range) | 14.24 (8.00—16.00) | |
| Range | 0.00—50.00 | |
| Avg dose post-delivery (mg) | 7394 (98.96) | |
| Median (interquartile range) | 9.72 (4.00—16.00) | |
| Range | 0.00—53.57 | |
| Avg dose exposure (mg) | 7394 (98.96) | |
| Median (interquartile range) | 14.09 (9.42—16.00) | |
| Range | 0.14—53.57 | |
| Total days buprenorphine before delivery (method 3) | 7299 (97.68) | |
| Median (interquartile range) | 63.00 (30.00—78.00) | |
| Range | 0.00—90.00 | |
| Total days buprenorphine after delivery (method 3) | 7299 (97.68) | |
| Median (interquartile range) | 30.00 (13.00—41.00) | |
| Range | 0.00—42.00 | |
| Total days supplied buprenorphine | 7299 (97.68) | |
| Median (interquartile range) | 90.00 (49.00—112.00) | |
| Range | 1.00—132.00 | |
| Avg dose BUP pre-delivery (mg) | 7298 (97.67) | |
| Median (interquartile range) | 14.12 (8.00—16.00) | |
| Range | 0.00—35.42 | |
| Avg dose BUP post-delivery (mg) | 7298 (97.67) | |
| Median (interquartile range) | 9.71 (4.00—16.00) | |
| Range | 0.00—42.67 | |
| Avg dose BUP exposure (mg) | 7298 (97.67) | |
| Median (interquartile range) | 13.98 (9.13—16.00) | |
| Range | 0.14—42.67 | |
| Combined pain : Yes | 7472 (100.00) | 5766/7472 (77.17) |
| Schizophrenia or personality disorder : Yes | 7472 (100.00) | 583/7472 (7.80) |
| Alcohol or other substance use : Yes | 7472 (100.00) | 3342/7472 (44.73) |
| Benzodiazepine or anticonvulsant use : Yes | 7472 (100.00) | 1077/7472 (14.41) |
| Maternal morbidity : Yes | 7472 (100.00) | 528/7472 (7.07) |
| Anxiety and depression combined : Yes | 7472 (100.00) | 3485/7472 (46.64) |
| Back pain : Yes | 7472 (100.00) | 2528/7472 (33.83) |
| Depression : Yes | 7472 (100.00) | 2946/7472 (39.43) |
| Bipolar disorder : Yes | 7472 (100.00) | 819/7472 (10.96) |
| Other substance use : Yes | 7472 (100.00) | 3197/7472 (42.79) |
| Tobacco use : Yes | 7472 (100.00) | 5196/7472 (69.54) |
| Med NSAIDS : Yes | 7472 (100.00) | 4602/7472 (61.59) |
| Schizophrenia psychotic disorders : Yes | 7472 (100.00) | 466/7472 (6.24) |
| Anxiety : Yes | 7472 (100.00) | 1608/7472 (21.52) |
| Med benzodiazepine use : Yes | 7472 (100.00) | 713/7472 (9.54) |
| Maternal morbidity : Yes | 7472 (100.00) | 528/7472 (7.07) |
| Dental pain : Yes | 7472 (100.00) | 298/7472 (3.99) |
| Alcohol use disorder : Yes | 7472 (100.00) | 507/7472 (6.79) |
| Med anticonvulsant use : Yes | 7472 (100.00) | 432/7472 (5.78) |
| Med muscle relaxant use : Yes | 7472 (100.00) | 371/7472 (4.97) |
| Personality disorder : Yes | 7472 (100.00) | 220/7472 (2.94) |
| Fibromyalgia : Yes | 7472 (100.00) | 383/7472 (5.13) |
| CDC SVI overall percentile ranking of all 4 themes | 7042 (94.25) | |
| Median (interquartile range) | 0.58 (0.37—0.79) | |
| Range | 0.00—1.00 |
| N | No outcome | Had outcome | Test Statistic | |
|---|---|---|---|---|
| (N=7345) | (N=127) | |||
| Year of delivery | 7472 (100.00) | F1,7470=36.05, P<0.00013 | ||
| Median (interquartile range) | 2016 (2014—2018) | 2018 (2016—2019) | ||
| Range | 2007—2020 | 2007—2020 | ||
| Age at delivery | 7472 (100.00) | F1,7470=0.04, P=0.83303 | ||
| Median (interquartile range) | 27 (24—31) | 27 (25—31) | ||
| Range | 17—44 | 19—41 | ||
| Number of Gestation weeks | 7472 (100.00) | F1,7470=3.29, P=0.06983 | ||
| Median (interquartile range) | 39 (37—39) | 38 (37—39) | ||
| Range | 21—42 | 25—42 | ||
| Race | 7472 (100.00) |
Χ2 4=31.51, P<0.00012 |
||
| American Indian or Alaska Native | 22/7345 (0.30) | 1/127 (0.79) | ||
| Asian or Pacific Islander | 11/7345 (0.15) | 0/127 (0.00) | ||
| Black of African American | 205/7345 (2.79) | 5/127 (3.94) | ||
| Other or Unknown | 47/7345 (0.64) | 6/127 (4.72) | ||
| White | 7060/7345 (96.12) | 115/127 (90.55) | ||
| Hispanic : Not Hispanic | 7465 (99.91) | 7273/7338 (99.11) | 125/127 (98.43) |
Χ2 1=0.67, P=0.41432 |
| Race/Ethnicity combined | 7472 (100.00) |
Χ2 4=29.81, P<0.00012 |
||
| Hispanic | 65/7345 (0.88) | 2/127 (1.57) | ||
| Non-Hispanic Asian | 11/7345 (0.15) | 0/127 (0.00) | ||
| Non-Hispanic Black | 204/7345 (2.78) | 5/127 (3.94) | ||
| Non-Hispanic Other | 49/7345 (0.67) | 6/127 (4.72) | ||
| Non-Hispanic White | 7016/7345 (95.52) | 114/127 (89.76) | ||
| Route of delivery : Vaginal | 7472 (100.00) | 4774/7345 (65.00) | 83/127 (65.35) |
Χ2 1=0.01, P=0.93322 |
| Number of previous pregnancies | 7335 (98.17) | F1,7333=0.97, P=0.32553 | ||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—23 | 0—11 | ||
| Final outcome | 7472 (100.00) |
Χ2 3=7472.00, P<0.00012 |
||
| Death | 0/7345 (0.00) | 30/127 (23.62) | ||
| Overdose | 0/7345 (0.00) | 97/127 (76.38) | ||
| Loss of enrollment | 709/7345 (9.65) | 0/127 (0.00) | ||
| Censored | 6636/7345 (90.35) | 0/127 (0.00) | ||
| Final outcome (w/o all payer data) | 7472 (100.00) |
Χ2 3=6026.67, P<0.00012 |
||
| Death | 0/7345 (0.00) | 11/127 (8.66) | ||
| Overdose | 0/7345 (0.00) | 91/127 (71.65) | ||
| Loss of enrollment | 709/7345 (9.65) | 25/127 (19.69) | ||
| Censored | 6636/7345 (90.35) | 0/127 (0.00) | ||
| Total days supplied MOUD (method 3) | 7472 (100.00) | F1,7470=11.45, P=0.00073 | ||
| Median (interquartile range) | 89 (47—112) | 73 (30—104) | ||
| Range | 1—132 | 2—131 | ||
| Total days supplied MOUD before delivery (method 3) | 7472 (100.00) | F1,7470=4.92, P=0.02653 | ||
| Median (interquartile range) | 62 (30—78) | 53 (17—77) | ||
| Range | 0—90 | 0—89 | ||
| Total days supplied MOUD after delivery (method 3) | 7472 (100.00) | F1,7470=15.99, P=0.00013 | ||
| Median (interquartile range) | 30 (13—41) | 21 (5—35) | ||
| Range | 0—42 | 0—42 | ||
| Avg dose pre-delivery (mg) | 7394 (98.96) | F1,7392=0.18, P=0.67513 | ||
| Median (interquartile range) | 14.25 (8.00—16.00) | 13.20 (8.00—16.00) | ||
| Range | 0.00—50.00 | 0.00—50.00 | ||
| Avg dose post-delivery (mg) | 7394 (98.96) | F1,7392=0.98, P=0.32173 | ||
| Median (interquartile range) | 9.76 (4.00—16.00) | 8.94 (0.00—16.00) | ||
| Range | 0.00—53.57 | 0.00—24.00 | ||
| Avg dose exposure (mg) | 7394 (98.96) | F1,7392=0.51, P=0.47583 | ||
| Median (interquartile range) | 14.09 (9.43—16.00) | 13.96 (8.74—16.00) | ||
| Range | 0.14—53.57 | 1.00—50.00 | ||
| Total days buprenorphine before delivery (method 3) | 7299 (97.68) | F1,7297=7.19, P=0.00743 | ||
| Median (interquartile range) | 63.00 (30.00—78.00) | 49.00 (16.00—76.33) | ||
| Range | 0.00—90.00 | 0.00—89.00 | ||
| Total days buprenorphine after delivery (method 3) | 7299 (97.68) | F1,7297=21.00, P<0.00013 | ||
| Median (interquartile range) | 30.00 (13.00—41.00) | 18.00 (3.33—34.33) | ||
| Range | 0.00—42.00 | 0.00—42.00 | ||
| Total days supplied buprenorphine | 7299 (97.68) | F1,7297=15.41, P=0.00013 | ||
| Median (interquartile range) | 90.00 (49.00—112.00) | 71.00 (28.00—103.33) | ||
| Range | 1.00—132.00 | 2.00—131.00 | ||
| Avg dose BUP pre-delivery (mg) | 7298 (97.67) | F1,7296=0.80, P=0.36993 | ||
| Median (interquartile range) | 14.13 (8.00—16.00) | 12.66 (8.00—16.00) | ||
| Range | 0.00—35.42 | 0.00—24.24 | ||
| Avg dose BUP post-delivery (mg) | 7298 (97.67) | F1,7296=0.49, P=0.48323 | ||
| Median (interquartile range) | 9.71 (4.00—16.00) | 9.13 (0.00—16.00) | ||
| Range | 0.00—42.67 | 0.00—24.00 | ||
| Avg dose BUP exposure (mg) | 7298 (97.67) | F1,7296=0.16, P=0.68873 | ||
| Median (interquartile range) | 13.98 (9.14—16.00) | 13.40 (8.67—16.00) | ||
| Range | 0.14—42.67 | 1.00—24.20 | ||
| Combined pain : Yes | 7472 (100.00) | 5677/7345 (77.29) | 89/127 (70.08) |
Χ2 1=3.69, P=0.05492 |
| Schizophrenia or personality disorder : Yes | 7472 (100.00) | 564/7345 (7.68) | 19/127 (14.96) |
Χ2 1=9.20, P=0.00242 |
| Alcohol or other substance use : Yes | 7472 (100.00) | 3275/7345 (44.59) | 67/127 (52.76) |
Χ2 1=3.37, P=0.06642 |
| Benzodiazepine or anticonvulsant use : Yes | 7472 (100.00) | 1052/7345 (14.32) | 25/127 (19.69) |
Χ2 1=2.91, P=0.08802 |
| Maternal morbidity : Yes | 7472 (100.00) | 519/7345 (7.07) | 9/127 (7.09) |
Χ2 1=0.00, P=0.99282 |
| Anxiety and depression combined : Yes | 7472 (100.00) | 3400/7345 (46.29) | 85/127 (66.93) |
Χ2 1=21.37, P<0.00012 |
| Back pain : Yes | 7472 (100.00) | 2496/7345 (33.98) | 32/127 (25.20) |
Χ2 1=4.30, P=0.03802 |
| Depression : Yes | 7472 (100.00) | 2868/7345 (39.05) | 78/127 (61.42) |
Χ2 1=26.16, P<0.00012 |
| Bipolar disorder : Yes | 7472 (100.00) | 790/7345 (10.76) | 29/127 (22.83) |
Χ2 1=18.66, P<0.00012 |
| Other substance use : Yes | 7472 (100.00) | 3130/7345 (42.61) | 67/127 (52.76) |
Χ2 1=5.25, P=0.02202 |
| Tobacco use : Yes | 7472 (100.00) | 5101/7345 (69.45) | 95/127 (74.80) |
Χ2 1=1.69, P=0.19362 |
| Med NSAIDS : Yes | 7472 (100.00) | 4530/7345 (61.67) | 72/127 (56.69) |
Χ2 1=1.31, P=0.25252 |
| Schizophrenia psychotic disorders : Yes | 7472 (100.00) | 448/7345 (6.10) | 18/127 (14.17) |
Χ2 1=13.92, P=0.00022 |
| Anxiety : Yes | 7472 (100.00) | 1562/7345 (21.27) | 46/127 (36.22) |
Χ2 1=16.53, P<0.00012 |
| Med benzodiazepine use : Yes | 7472 (100.00) | 701/7345 (9.54) | 12/127 (9.45) |
Χ2 1=0.00, P=0.97122 |
| Maternal morbidity : Yes | 7472 (100.00) | 519/7345 (7.07) | 9/127 (7.09) |
Χ2 1=0.00, P=0.99282 |
| Dental pain : Yes | 7472 (100.00) | 291/7345 (3.96) | 7/127 (5.51) |
Χ2 1=0.78, P=0.37622 |
| Alcohol use disorder : Yes | 7472 (100.00) | 485/7345 (6.60) | 22/127 (17.32) |
Χ2 1=22.68, P<0.00012 |
| Med anticonvulsant use : Yes | 7472 (100.00) | 416/7345 (5.66) | 16/127 (12.60) |
Χ2 1=11.02, P=0.00092 |
| Med muscle relaxant use : Yes | 7472 (100.00) | 363/7345 (4.94) | 8/127 (6.30) |
Χ2 1=0.49, P=0.48522 |
| Personality disorder : Yes | 7472 (100.00) | 214/7345 (2.91) | 6/127 (4.72) |
Χ2 1=1.43, P=0.23132 |
| Fibromyalgia : Yes | 7472 (100.00) | 376/7345 (5.12) | 7/127 (5.51) |
Χ2 1=0.04, P=0.84232 |
| CDC SVI overall percentile ranking of all 4 themes | 7042 (94.25) | F1,7040=0.80, P=0.37143 | ||
| Median (interquartile range) | 0.58 (0.37—0.79) | 0.54 (0.31—0.83) | ||
| Range | 0.00—1.00 | 0.00—1.00 |
| N | All | |
|---|---|---|
| (N=7472) | ||
| MOUD pre-delivery (method 1) | 7472 (100.00) | |
| No MOUD | 634/7472 (8.49) | |
| MOUD | 6838/7472 (91.51) | |
| MOUD pre-delivery (method 2) | 7472 (100.00) | |
| No MOUD | 634/7472 (8.49) | |
| MOUD | 6838/7472 (91.51) | |
| MOUD pre-delivery (method 3) | 7472 (100.00) | |
| No MOUD | 638/7472 (8.54) | |
| MOUD | 6834/7472 (91.46) | |
| MOUD post-delivery (method 1) | 7472 (100.00) | |
| No MOUD | 1494/7472 (19.99) | |
| MOUD | 5978/7472 (80.01) | |
| MOUD post-delivery (method 2) | 7472 (100.00) | |
| No MOUD | 1300/7472 (17.40) | |
| MOUD | 6172/7472 (82.60) | |
| MOUD post-delivery (method 3) | 7472 (100.00) | |
| No MOUD | 898/7472 (12.02) | |
| MOUD | 6574/7472 (87.98) | |
| MOUD pre and post (method 1) | 7472 (100.00) | |
| No MOUD | 0/7472 (0.00) | |
| Both pre and post | 5344/7472 (71.52) | |
| Either pre or post | 2128/7472 (28.48) | |
| MOUD pre and post (method 2) | 7472 (100.00) | |
| No MOUD | 0/7472 (0.00) | |
| Both pre and post | 5538/7472 (74.12) | |
| Either pre or post | 1934/7472 (25.88) | |
| MOUD pre and post (method 3) | 7472 (100.00) | |
| No MOUD | 0/7472 (0.00) | |
| Both pre and post | 5936/7472 (79.44) | |
| Either pre or post | 1536/7472 (20.56) |
| N | Both pre and post | Either pre or post | Test Statistic | |
|---|---|---|---|---|
| (N=5936) | (N=1536) | |||
| Year of delivery | 7472 (100.00) | F1,7470=6.08, P=0.01373 | ||
| Median (interquartile range) | 2016 (2014—2018) | 2016 (2014—2018) | ||
| Range | 2007—2020 | 2007—2020 | ||
| Year of delivery as categorical | 7472 (100.00) |
Χ2 13=53.65, P<0.00012 |
||
| 2007 | 25/5936 (0.42) | 7/1536 (0.46) | ||
| 2008 | 41/5936 (0.69) | 18/1536 (1.17) | ||
| 2009 | 52/5936 (0.88) | 29/1536 (1.89) | ||
| 2010 | 112/5936 (1.89) | 30/1536 (1.95) | ||
| 2011 | 146/5936 (2.46) | 46/1536 (2.99) | ||
| 2012 | 223/5936 (3.76) | 47/1536 (3.06) | ||
| 2013 | 438/5936 (7.38) | 83/1536 (5.40) | ||
| 2014 | 684/5936 (11.52) | 127/1536 (8.27) | ||
| 2015 | 821/5936 (13.83) | 181/1536 (11.78) | ||
| 2016 | 769/5936 (12.95) | 216/1536 (14.06) | ||
| 2017 | 635/5936 (10.70) | 194/1536 (12.63) | ||
| 2018 | 621/5936 (10.46) | 183/1536 (11.91) | ||
| 2019 | 663/5936 (11.17) | 204/1536 (13.28) | ||
| 2020 | 706/5936 (11.89) | 171/1536 (11.13) | ||
| Age at delivery | 7472 (100.00) | F1,7470=0.46, P=0.49643 | ||
| Median (interquartile range) | 27 (24—31) | 27 (24—31) | ||
| Range | 17—44 | 17—44 | ||
| Number of Gestation weeks | 7472 (100.00) | F1,7470=20.74, P<0.00013 | ||
| Median (interquartile range) | 39 (37—39) | 38 (37—39) | ||
| Range | 21—42 | 23—42 | ||
| Race | 7472 (100.00) |
Χ2 4=10.38, P=0.03462 |
||
| American Indian or Alaska Native | 16/5936 (0.27) | 7/1536 (0.46) | ||
| Asian or Pacific Islander | 9/5936 (0.15) | 2/1536 (0.13) | ||
| Black of African American | 153/5936 (2.58) | 57/1536 (3.71) | ||
| Other or Unknown | 37/5936 (0.62) | 16/1536 (1.04) | ||
| White | 5721/5936 (96.38) | 1454/1536 (94.66) | ||
| Hispanic : Not Hispanic | 7465 (99.91) | 5879/5933 (99.09) | 1519/1532 (99.15) |
Χ2 1=0.05, P=0.81972 |
| Race/Ethnicity combined | 7472 (100.00) |
Χ2 4=13.85, P=0.00782 |
||
| Hispanic | 54/5936 (0.91) | 13/1536 (0.85) | ||
| Non-Hispanic Asian | 9/5936 (0.15) | 2/1536 (0.13) | ||
| Non-Hispanic Black | 153/5936 (2.58) | 56/1536 (3.65) | ||
| Non-Hispanic Other | 35/5936 (0.59) | 20/1536 (1.30) | ||
| Non-Hispanic White | 5685/5936 (95.77) | 1445/1536 (94.08) | ||
| Route of delivery : Vaginal | 7472 (100.00) | 3822/5936 (64.39) | 1035/1536 (67.38) |
Χ2 1=4.81, P=0.02822 |
| Number of previous pregnancies | 7335 (98.17) | F1,7333=4.07, P=0.04383 | ||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—23 | 0—23 | ||
| Final outcome | 7472 (100.00) |
Χ2 3=34.63, P<0.00012 |
||
| Death | 25/5936 (0.42) | 5/1536 (0.33) | ||
| Overdose | 62/5936 (1.04) | 35/1536 (2.28) | ||
| Loss of enrollment | 519/5936 (8.74) | 190/1536 (12.37) | ||
| Censored | 5330/5936 (89.79) | 1306/1536 (85.03) | ||
| Final outcome 3 levels | 7472 (100.00) |
Χ2 2=14.76, P=0.00062 |
||
| Death | 25/5936 (0.42) | 5/1536 (0.33) | ||
| Overdose | 62/5936 (1.04) | 35/1536 (2.28) | ||
| Censored | 5849/5936 (98.53) | 1496/1536 (97.40) | ||
| Total days supplied MOUD | 7472 (100.00) | F1,7470=5071.00, P<0.00013 | ||
| Median (interquartile range) | 108 (84—122) | 29 (14—42) | ||
| Range | 7—132 | 1—90 | ||
| Total days supplied MOUD before delivery | 7472 (100.00) | F1,7470=3779.50, P<0.00013 | ||
| Median (interquartile range) | 84 (60—90) | 11 (0—35) | ||
| Range | 1—90 | 0—90 | ||
| Total days supplied MOUD after delivery | 7472 (100.00) | F1,7470=1748.75, P<0.00013 | ||
| Median (interquartile range) | 30 (21—42) | 0 (0—21) | ||
| Range | 0—42 | 0—42 | ||
| Total days supplied MOUD (method 2) | 7472 (100.00) | F1,7470=4954.77, P<0.00013 | ||
| Median (interquartile range) | 112 (84—129) | 29 (14—42) | ||
| Range | 7—132 | 1—132 | ||
| Total days supplied MOUD before delivery (method 2) | 7472 (100.00) | F1,7470=3779.50, P<0.00013 | ||
| Median (interquartile range) | 84 (60—90) | 11 (0—35) | ||
| Range | 1—90 | 0—90 | ||
| Total days supplied MOUD after delivery (method 2) | 7472 (100.00) | F1,7470=2132.86, P<0.00013 | ||
| Median (interquartile range) | 35 (24—42) | 0 (0—23) | ||
| Range | 0—42 | 0—42 | ||
| Total days supplied MOUD (method 3) | 7472 (100.00) | F1,7470=5107.13, P<0.00013 | ||
| Median (interquartile range) | 100 (76—116) | 22 (11—34) | ||
| Range | 7—132 | 1—89 | ||
| Total days supplied MOUD before delivery (method 3) | 7472 (100.00) | F1,7470=3154.36, P<0.00013 | ||
| Median (interquartile range) | 69 (48—80) | 10 (0—32) | ||
| Range | 1—90 | 0—89 | ||
| Total days supplied MOUD after delivery (method 3) | 7472 (100.00) | F1,7470=4221.19, P<0.00013 | ||
| Median (interquartile range) | 35 (23—41) | 0 (0—11) | ||
| Range | 1—42 | 0—41 | ||
| Avg dose pre-delivery (mg) | 7394 (98.96) | F1,7392=750.98, P<0.00013 | ||
| Median (interquartile range) | 15.00 (9.94—16.00) | 7.37 (0.00—16.00) | ||
| Range | 0.25—50.00 | 0.00—50.00 | ||
| Avg dose post-delivery (mg) | 7394 (98.96) | F1,7392=858.54, P<0.00013 | ||
| Median (interquartile range) | 12.00 (8.00—16.00) | 0.00 (0.00—10.76) | ||
| Range | 0.00—50.00 | 0.00—53.57 | ||
| Avg dose exposure (mg) | 7394 (98.96) | F1,7392=1.73, P=0.18813 | ||
| Median (interquartile range) | 14.04 (9.87—16.00) | 14.55 (8.00—16.00) | ||
| Range | 0.25—50.00 | 0.14—53.57 | ||
| Total days buprenorphine before delivery (method 3) | 7299 (97.68) | F1,7297=2768.33, P<0.00013 | ||
| Median (interquartile range) | 69.00 (48.00—80.00) | 14.00 (0.00—33.00) | ||
| Range | 0.00—90.00 | 0.00—89.00 | ||
| Total days buprenorphine after delivery (method 3) | 7299 (97.68) | F1,7297=3874.92, P<0.00013 | ||
| Median (interquartile range) | 35.00 (23.00—41.00) | 0.00 (0.00—9.00) | ||
| Range | 0.00—42.00 | 0.00—41.00 | ||
| Total days supplied buprenorphine | 7299 (97.68) | F1,7297=4518.19, P<0.00013 | ||
| Median (interquartile range) | 100.00 (76.00—116.00) | 22.00 (11.17—35.00) | ||
| Range | 4.00—132.00 | 1.00—89.00 | ||
| Avg dose BUP pre-delivery (mg) | 7298 (97.67) | F1,7296=753.31, P<0.00013 | ||
| Median (interquartile range) | 14.86 (9.67—16.00) | 7.47 (0.00—15.71) | ||
| Range | 0.00—35.42 | 0.00—29.71 | ||
| Avg dose BUP post-delivery (mg) | 7298 (97.67) | F1,7296=927.21, P<0.00013 | ||
| Median (interquartile range) | 12.00 (8.00—16.00) | 0.00 (0.00—9.63) | ||
| Range | 0.00—33.24 | 0.00—42.67 | ||
| Avg dose BUP exposure (mg) | 7298 (97.67) | F1,7296=0.00, P=0.99873 | ||
| Median (interquartile range) | 13.98 (9.75—16.00) | 14.00 (8.00—16.00) | ||
| Range | 0.25—34.47 | 0.14—42.67 | ||
| Combined pain : Yes | 7472 (100.00) | 4591/5936 (77.34) | 1175/1536 (76.50) |
Χ2 1=0.49, P=0.48232 |
| Schizophrenia or personality disorder : Yes | 7472 (100.00) | 434/5936 (7.31) | 149/1536 (9.70) |
Χ2 1=9.68, P=0.00192 |
| Alcohol or other substance use : Yes | 7472 (100.00) | 2586/5936 (43.56) | 756/1536 (49.22) |
Χ2 1=15.78, P=0.00012 |
| Benzodiazepine or anticonvulsant use : Yes | 7472 (100.00) | 859/5936 (14.47) | 218/1536 (14.19) |
Χ2 1=0.08, P=0.78192 |
| Maternal morbidity : Yes | 7472 (100.00) | 407/5936 (6.86) | 121/1536 (7.88) |
Χ2 1=1.94, P=0.16392 |
| Anxiety and depression combined : Yes | 7472 (100.00) | 2745/5936 (46.24) | 740/1536 (48.18) |
Χ2 1=1.83, P=0.17572 |
| Back pain : Yes | 7472 (100.00) | 2030/5936 (34.20) | 498/1536 (32.42) |
Χ2 1=1.72, P=0.18972 |
| Depression : Yes | 7472 (100.00) | 2314/5936 (38.98) | 632/1536 (41.15) |
Χ2 1=2.39, P=0.12202 |
| Bipolar disorder : Yes | 7472 (100.00) | 648/5936 (10.92) | 171/1536 (11.13) |
Χ2 1=0.06, P=0.80882 |
| Other substance use : Yes | 7472 (100.00) | 2460/5936 (41.44) | 737/1536 (47.98) |
Χ2 1=21.32, P<0.00012 |
| Tobacco use : Yes | 7472 (100.00) | 4117/5936 (69.36) | 1079/1536 (70.25) |
Χ2 1=0.46, P=0.49892 |
| Med NSAIDS : Yes | 7472 (100.00) | 3667/5936 (61.78) | 935/1536 (60.87) |
Χ2 1=0.42, P=0.51652 |
| Schizophrenia psychotic disorders : Yes | 7472 (100.00) | 353/5936 (5.95) | 113/1536 (7.36) |
Χ2 1=4.15, P=0.04172 |
| Anxiety : Yes | 7472 (100.00) | 1260/5936 (21.23) | 348/1536 (22.66) |
Χ2 1=1.48, P=0.22422 |
| Med benzodiazepine use : Yes | 7472 (100.00) | 564/5936 (9.50) | 149/1536 (9.70) |
Χ2 1=0.06, P=0.81282 |
| Maternal morbidity : Yes | 7472 (100.00) | 407/5936 (6.86) | 121/1536 (7.88) |
Χ2 1=1.94, P=0.16392 |
| Dental pain : Yes | 7472 (100.00) | 224/5936 (3.77) | 74/1536 (4.82) |
Χ2 1=3.47, P=0.06232 |
| Alcohol use disorder : Yes | 7472 (100.00) | 377/5936 (6.35) | 130/1536 (8.46) |
Χ2 1=8.61, P=0.00332 |
| Med anticonvulsant use : Yes | 7472 (100.00) | 351/5936 (5.91) | 81/1536 (5.27) |
Χ2 1=0.92, P=0.33842 |
| Med muscle relaxant use : Yes | 7472 (100.00) | 264/5936 (4.45) | 107/1536 (6.97) |
Χ2 1=16.41, P=0.00012 |
| Personality disorder : Yes | 7472 (100.00) | 154/5936 (2.59) | 66/1536 (4.30) |
Χ2 1=12.38, P=0.00042 |
| Fibromyalgia : Yes | 7472 (100.00) | 299/5936 (5.04) | 84/1536 (5.47) |
Χ2 1=0.47, P=0.49412 |
| CDC SVI overall percentile ranking of all 4 themes | 7042 (94.25) | F1,7040=3.35, P=0.06733 | ||
| Median (interquartile range) | 0.57 (0.36—0.78) | 0.60 (0.38—0.80) | ||
| Range | 0.00—1.00 | 0.00—1.00 |
| N | Only pre | Only post | Both pre and post | Test Statistic | |
|---|---|---|---|---|---|
| (N=898) | (N=638) | (N=5936) | |||
| Year of delivery | 7472 (100.00) | F2,7469=4.01, P=0.01821 | |||
| Median (interquartile range) | 2016 (2015—2018) | 2016 (2014—2019) | 2016 (2014—2018) | ||
| Range | 2007—2020 | 2007—2020 | 2007—2020 | ||
| Year of delivery as categorical | 7472 (100.00) |
Χ2 26=167.95, P<0.00012 |
|||
| 2007 | 1/898 (0.11) | 6/638 (0.94) | 25/5936 (0.42) | ||
| 2008 | 3/898 (0.33) | 15/638 (2.35) | 41/5936 (0.69) | ||
| 2009 | 10/898 (1.11) | 19/638 (2.98) | 52/5936 (0.88) | ||
| 2010 | 6/898 (0.67) | 24/638 (3.76) | 112/5936 (1.89) | ||
| 2011 | 19/898 (2.12) | 27/638 (4.23) | 146/5936 (2.46) | ||
| 2012 | 28/898 (3.12) | 19/638 (2.98) | 223/5936 (3.76) | ||
| 2013 | 40/898 (4.45) | 43/638 (6.74) | 438/5936 (7.38) | ||
| 2014 | 79/898 (8.80) | 48/638 (7.52) | 684/5936 (11.52) | ||
| 2015 | 121/898 (13.47) | 60/638 (9.40) | 821/5936 (13.83) | ||
| 2016 | 155/898 (17.26) | 61/638 (9.56) | 769/5936 (12.95) | ||
| 2017 | 124/898 (13.81) | 70/638 (10.97) | 635/5936 (10.70) | ||
| 2018 | 125/898 (13.92) | 58/638 (9.09) | 621/5936 (10.46) | ||
| 2019 | 113/898 (12.58) | 91/638 (14.26) | 663/5936 (11.17) | ||
| 2020 | 74/898 (8.24) | 97/638 (15.20) | 706/5936 (11.89) | ||
| Age at delivery | 7472 (100.00) | F2,7469=0.32, P=0.72301 | |||
| Median (interquartile range) | 27 (24—31) | 27 (24—31) | 27 (24—31) | ||
| Range | 18—43 | 17—44 | 17—44 | ||
| Number of Gestation weeks | 7472 (100.00) | F2,7469=13.25, P<0.00011 | |||
| Median (interquartile range) | 39 (37—39) | 38 (37—39) | 39 (37—39) | ||
| Range | 24—42 | 23—42 | 21—42 | ||
| Race | 7472 (100.00) |
Χ2 8=11.75, P=0.16262 |
|||
| American Indian or Alaska Native | 4/898 (0.45) | 3/638 (0.47) | 16/5936 (0.27) | ||
| Asian or Pacific Islander | 1/898 (0.11) | 1/638 (0.16) | 9/5936 (0.15) | ||
| Black of African American | 35/898 (3.90) | 22/638 (3.45) | 153/5936 (2.58) | ||
| Other or Unknown | 11/898 (1.22) | 5/638 (0.78) | 37/5936 (0.62) | ||
| White | 847/898 (94.32) | 607/638 (95.14) | 5721/5936 (96.38) | ||
| Hispanic : Not Hispanic | 7465 (99.91) | 886/895 (98.99) | 633/637 (99.37) | 5879/5933 (99.09) |
Χ2 2=0.65, P=0.72302 |
| Race/Ethnicity combined | 7472 (100.00) |
Χ2 8=15.31, P=0.05342 |
|||
| Hispanic | 9/898 (1.00) | 4/638 (0.63) | 54/5936 (0.91) | ||
| Non-Hispanic Asian | 1/898 (0.11) | 1/638 (0.16) | 9/5936 (0.15) | ||
| Non-Hispanic Black | 34/898 (3.79) | 22/638 (3.45) | 153/5936 (2.58) | ||
| Non-Hispanic Other | 13/898 (1.45) | 7/638 (1.10) | 35/5936 (0.59) | ||
| Non-Hispanic White | 841/898 (93.65) | 604/638 (94.67) | 5685/5936 (95.77) | ||
| Route of delivery : Vaginal | 7472 (100.00) | 614/898 (68.37) | 421/638 (65.99) | 3822/5936 (64.39) |
Χ2 2=5.75, P=0.05652 |
| Number of previous pregnancies | 7335 (98.17) | F2,7332=2.23, P=0.10741 | |||
| Median (interquartile range) | 2 (1—3) | 2 (1—3) | 2 (1—3) | ||
| Range | 0—19 | 0—23 | 0—23 | ||
| Final outcome | 7472 (100.00) |
Χ2 6=39.01, P<0.00012 |
|||
| Death | 3/898 (0.33) | 2/638 (0.31) | 25/5936 (0.42) | ||
| Overdose | 19/898 (2.12) | 16/638 (2.51) | 62/5936 (1.04) | ||
| Loss of enrollment | 100/898 (11.14) | 90/638 (14.11) | 519/5936 (8.74) | ||
| Censored | 776/898 (86.41) | 530/638 (83.07) | 5330/5936 (89.79) | ||
| Final outcome 3 levels | 7472 (100.00) |
Χ2 4=15.21, P=0.00432 |
|||
| Death | 3/898 (0.33) | 2/638 (0.31) | 25/5936 (0.42) | ||
| Overdose | 19/898 (2.12) | 16/638 (2.51) | 62/5936 (1.04) | ||
| Censored | 876/898 (97.55) | 620/638 (97.18) | 5849/5936 (98.53) | ||
| Total days supplied MOUD | 7472 (100.00) | F2,7469=2556.49, P<0.00011 | |||
| Median (interquartile range) | 30 (15—56) | 28 (14—33) | 108 (84—122) | ||
| Range | 1—90 | 1—70 | 7—132 | ||
| Total days supplied MOUD before delivery | 7472 (100.00) | F2,7469=2174.12, P<0.00011 | |||
| Median (interquartile range) | 30 (15—56) | 0 (0—0) | 84 (60—90) | ||
| Range | 1—90 | 0—28 | 1—90 | ||
| Total days supplied MOUD after delivery | 7472 (100.00) | F2,7469=1437.41, P<0.00011 | |||
| Median (interquartile range) | 0 (0—0) | 28 (14—33) | 30 (21—42) | ||
| Range | 0—0 | 1—42 | 0—42 | ||
| Total days supplied MOUD (method 2) | 7472 (100.00) | F2,7469=2502.29, P<0.00011 | |||
| Median (interquartile range) | 30 (15—56) | 28 (14—33) | 112 (84—129) | ||
| Range | 1—132 | 1—70 | 7—132 | ||
| Total days supplied MOUD before delivery (method 2) | 7472 (100.00) | F2,7469=2174.12, P<0.00011 | |||
| Median (interquartile range) | 30 (15—56) | 0 (0—0) | 84 (60—90) | ||
| Range | 1—90 | 0—28 | 1—90 | ||
| Total days supplied MOUD after delivery (method 2) | 7472 (100.00) | F2,7469=1572.78, P<0.00011 | |||
| Median (interquartile range) | 0 (0—0) | 28 (14—33) | 35 (24—42) | ||
| Range | 0—42 | 1—42 | 0—42 | ||
| Total days supplied MOUD (method 3) | 7472 (100.00) | F2,7469=2608.87, P<0.00011 | |||
| Median (interquartile range) | 30 (14—49) | 14 (7—25) | 100 (76—116) | ||
| Range | 1—89 | 1—41 | 7—132 | ||
| Total days supplied MOUD before delivery (method 3) | 7472 (100.00) | F2,7469=1884.96, P<0.00011 | |||
| Median (interquartile range) | 30 (14—49) | 0 (0—0) | 69 (48—80) | ||
| Range | 1—89 | 0—0 | 1—90 | ||
| Total days supplied MOUD after delivery (method 3) | 7472 (100.00) | F2,7469=2453.64, P<0.00011 | |||
| Median (interquartile range) | 0 (0—0) | 14 (7—25) | 35 (23—41) | ||
| Range | 0—0 | 1—41 | 1—42 | ||
| Avg dose pre-delivery (mg) | 7394 (98.96) | F2,7391=1043.59, P<0.00011 | |||
| Median (interquartile range) | 13.90 (8.00—16.00) | 0.00 (0.00—0.00) | 15.00 (9.94—16.00) | ||
| Range | 0.14—50.00 | 0.00—0.00 | 0.25—50.00 | ||
| Avg dose post-delivery (mg) | 7394 (98.96) | F2,7391=1408.35, P<0.00011 | |||
| Median (interquartile range) | 0.00 (0.00—0.00) | 15.76 (8.12—16.00) | 12.00 (8.00—16.00) | ||
| Range | 0.00—0.00 | 0.80—53.57 | 0.00—50.00 | ||
| Avg dose exposure (mg) | 7394 (98.96) | F2,7391=6.55, P=0.00141 | |||
| Median (interquartile range) | 13.90 (8.00—16.00) | 15.76 (8.12—16.00) | 14.04 (9.87—16.00) | ||
| Range | 0.14—50.00 | 0.80—53.57 | 0.25—50.00 | ||
| Total days buprenorphine before delivery (method 3) | 7299 (97.68) | F2,7296=1632.75, P<0.00011 | |||
| Median (interquartile range) | 30.00 (14.00—49.00) | 0.00 (0.00—0.00) | 69.00 (48.00—80.00) | ||
| Range | 1.00—89.00 | 0.00—0.00 | 0.00—90.00 | ||
| Total days buprenorphine after delivery (method 3) | 7299 (97.68) | F2,7296=2232.06, P<0.00011 | |||
| Median (interquartile range) | 0.00 (0.00—0.00) | 14.50 (7.00—25.00) | 35.00 (23.00—41.00) | ||
| Range | 0.00—0.00 | 1.00—41.00 | 0.00—42.00 | ||
| Total days supplied buprenorphine | 7299 (97.68) | F2,7296=2300.69, P<0.00011 | |||
| Median (interquartile range) | 30.00 (14.00—49.00) | 14.50 (7.00—25.00) | 100.00 (76.00—116.00) | ||
| Range | 1.00—89.00 | 1.00—41.00 | 4.00—132.00 | ||
| Avg dose BUP pre-delivery (mg) | 7298 (97.67) | F2,7295=997.58, P<0.00011 | |||
| Median (interquartile range) | 13.33 (8.00—16.00) | 0.00 (0.00—0.00) | 14.86 (9.67—16.00) | ||
| Range | 0.14—29.71 | 0.00—0.00 | 0.00—35.42 | ||
| Avg dose BUP post-delivery (mg) | 7298 (97.67) | F2,7295=1365.44, P<0.00011 | |||
| Median (interquartile range) | 0.00 (0.00—0.00) | 15.30 (8.00—16.00) | 12.00 (8.00—16.00) | ||
| Range | 0.00—0.00 | 0.80—42.67 | 0.00—33.24 | ||
| Avg dose BUP exposure (mg) | 7298 (97.67) | F2,7295=3.99, P=0.01851 | |||
| Median (interquartile range) | 13.33 (8.00—16.00) | 15.30 (8.00—16.00) | 13.98 (9.75—16.00) | ||
| Range | 0.14—29.71 | 0.80—42.67 | 0.25—34.47 | ||
| Combined pain : Yes | 7472 (100.00) | 702/898 (78.17) | 473/638 (74.14) | 4591/5936 (77.34) |
Χ2 2=3.94, P=0.13932 |
| Schizophrenia or personality disorder : Yes | 7472 (100.00) | 83/898 (9.24) | 66/638 (10.34) | 434/5936 (7.31) |
Χ2 2=10.31, P=0.00582 |
| Alcohol or other substance use : Yes | 7472 (100.00) | 441/898 (49.11) | 315/638 (49.37) | 2586/5936 (43.56) |
Χ2 2=15.79, P=0.00042 |
| Benzodiazepine or anticonvulsant use : Yes | 7472 (100.00) | 131/898 (14.59) | 87/638 (13.64) | 859/5936 (14.47) |
Χ2 2=0.35, P=0.83932 |
| Maternal morbidity : Yes | 7472 (100.00) | 69/898 (7.68) | 52/638 (8.15) | 407/5936 (6.86) |
Χ2 2=2.06, P=0.35682 |
| Anxiety and depression combined : Yes | 7472 (100.00) | 403/898 (44.88) | 337/638 (52.82) | 2745/5936 (46.24) |
Χ2 2=11.29, P=0.00352 |
| Back pain : Yes | 7472 (100.00) | 308/898 (34.30) | 190/638 (29.78) | 2030/5936 (34.20) |
Χ2 2=5.12, P=0.07732 |
| Depression : Yes | 7472 (100.00) | 338/898 (37.64) | 294/638 (46.08) | 2314/5936 (38.98) |
Χ2 2=13.52, P=0.00122 |
| Bipolar disorder : Yes | 7472 (100.00) | 110/898 (12.25) | 61/638 (9.56) | 648/5936 (10.92) |
Χ2 2=2.82, P=0.24412 |
| Other substance use : Yes | 7472 (100.00) | 434/898 (48.33) | 303/638 (47.49) | 2460/5936 (41.44) |
Χ2 2=21.43, P<0.00012 |
| Tobacco use : Yes | 7472 (100.00) | 651/898 (72.49) | 428/638 (67.08) | 4117/5936 (69.36) |
Χ2 2=5.61, P=0.06052 |
| Med NSAIDS : Yes | 7472 (100.00) | 551/898 (61.36) | 384/638 (60.19) | 3667/5936 (61.78) |
Χ2 2=0.64, P=0.72732 |
| Schizophrenia psychotic disorders : Yes | 7472 (100.00) | 64/898 (7.13) | 49/638 (7.68) | 353/5936 (5.95) |
Χ2 2=4.34, P=0.11402 |
| Anxiety : Yes | 7472 (100.00) | 208/898 (23.16) | 140/638 (21.94) | 1260/5936 (21.23) |
Χ2 2=1.81, P=0.40552 |
| Med benzodiazepine use : Yes | 7472 (100.00) | 93/898 (10.36) | 56/638 (8.78) | 564/5936 (9.50) |
Χ2 2=1.13, P=0.56742 |
| Maternal morbidity : Yes | 7472 (100.00) | 69/898 (7.68) | 52/638 (8.15) | 407/5936 (6.86) |
Χ2 2=2.06, P=0.35682 |
| Dental pain : Yes | 7472 (100.00) | 44/898 (4.90) | 30/638 (4.70) | 224/5936 (3.77) |
Χ2 2=3.51, P=0.17272 |
| Alcohol use disorder : Yes | 7472 (100.00) | 66/898 (7.35) | 64/638 (10.03) | 377/5936 (6.35) |
Χ2 2=12.85, P=0.00162 |
| Med anticonvulsant use : Yes | 7472 (100.00) | 48/898 (5.35) | 33/638 (5.17) | 351/5936 (5.91) |
Χ2 2=0.94, P=0.62602 |
| Med muscle relaxant use : Yes | 7472 (100.00) | 57/898 (6.35) | 50/638 (7.84) | 264/5936 (4.45) |
Χ2 2=18.16, P=0.00012 |
| Personality disorder : Yes | 7472 (100.00) | 35/898 (3.90) | 31/638 (4.86) | 154/5936 (2.59) |
Χ2 2=13.58, P=0.00112 |
| Fibromyalgia : Yes | 7472 (100.00) | 55/898 (6.12) | 29/638 (4.55) | 299/5936 (5.04) |
Χ2 2=2.38, P=0.30412 |
| CDC SVI overall percentile ranking of all 4 themes | 7042 (94.25) | F2,7039=2.85, P=0.05801 | |||
| Median (interquartile range) | 0.61 (0.38—0.81) | 0.58 (0.37—0.78) | 0.57 (0.36—0.78) | ||
| Range | 0.00—1.00 | 0.00—1.00 | 0.00—1.00 |
Call: survfit(formula = Surv(days.to.event, outcome.bin) ~ 1, data = moud)
n events median 0.95LCL 0.95UCL
[1,] 7472 127 NA NA NA
Min. 1st Qu. Median Mean 3rd Qu. Max.
2.0 97.0 185.0 178.3 261.0 323.0
| time | probability |
|---|---|
| 2 | 0.9998662 |
| 7 | 0.9997323 |
| 8 | 0.9994647 |
| 17 | 0.9993308 |
| 18 | 0.9991970 |
| 19 | 0.9990632 |
| 27 | 0.9989293 |
| 32 | 0.9987955 |
| 34 | 0.9986617 |
| 35 | 0.9983940 |
| 41 | 0.9982602 |
| 45 | 0.9979925 |
| 47 | 0.9978587 |
| 52 | 0.9977248 |
| 59 | 0.9974572 |
| 60 | 0.9973233 |
| 61 | 0.9971895 |
| 63 | 0.9970557 |
| 65 | 0.9969218 |
| 66 | 0.9967880 |
| 69 | 0.9966542 |
| 70 | 0.9965203 |
| 75 | 0.9963865 |
| 77 | 0.9962527 |
| 87 | 0.9961188 |
| 93 | 0.9959850 |
| 95 | 0.9958512 |
| 97 | 0.9957173 |
| 101 | 0.9954497 |
| 110 | 0.9953158 |
| 111 | 0.9951820 |
| 112 | 0.9950482 |
| 118 | 0.9949143 |
| 120 | 0.9947805 |
| 121 | 0.9946467 |
| 125 | 0.9945128 |
| 128 | 0.9943790 |
| 131 | 0.9942452 |
| 138 | 0.9939775 |
| 140 | 0.9938437 |
| 144 | 0.9937099 |
| 147 | 0.9935760 |
| 151 | 0.9933084 |
| 153 | 0.9931745 |
| 156 | 0.9929069 |
| 166 | 0.9927730 |
| 171 | 0.9926392 |
| 173 | 0.9925054 |
| 175 | 0.9923715 |
| 177 | 0.9922377 |
| 178 | 0.9921039 |
| 181 | 0.9919700 |
| 182 | 0.9918362 |
| 184 | 0.9917024 |
| 185 | 0.9915685 |
| 188 | 0.9913009 |
| 193 | 0.9911670 |
| 204 | 0.9910332 |
| 208 | 0.9908994 |
| 211 | 0.9907655 |
| 213 | 0.9906317 |
| 215 | 0.9904979 |
| 216 | 0.9903640 |
| 217 | 0.9900964 |
| 220 | 0.9899625 |
| 222 | 0.9898287 |
| 223 | 0.9896949 |
| 228 | 0.9894272 |
| 229 | 0.9892934 |
| 233 | 0.9891595 |
| 235 | 0.9890257 |
| 236 | 0.9888919 |
| 239 | 0.9887580 |
| 240 | 0.9884904 |
| 245 | 0.9883565 |
| 246 | 0.9880889 |
| 247 | 0.9879550 |
| 250 | 0.9878212 |
| 253 | 0.9876874 |
| 254 | 0.9875535 |
| 258 | 0.9874197 |
| 261 | 0.9871520 |
| 262 | 0.9870182 |
| 263 | 0.9868844 |
| 265 | 0.9867505 |
| 267 | 0.9866167 |
| 268 | 0.9864829 |
| 270 | 0.9863490 |
| 271 | 0.9862152 |
| 274 | 0.9859475 |
| 275 | 0.9858137 |
| 279 | 0.9856799 |
| 287 | 0.9854122 |
| 289 | 0.9852784 |
| 290 | 0.9851445 |
| 295 | 0.9850107 |
| 296 | 0.9848769 |
| 298 | 0.9846092 |
| 300 | 0.9844754 |
| 301 | 0.9843415 |
| 302 | 0.9842077 |
| 304 | 0.9840739 |
| 305 | 0.9839400 |
| 308 | 0.9836724 |
| 310 | 0.9834047 |
| 313 | 0.9832709 |
| 316 | 0.9831370 |
| 319 | 0.9830032 |
| 323 | 0.9830032 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 | 0 | 108 | 1 | 178.4 | 179 | 108.1 | 21.4 | 43.4 | 99.0 | 188.0 | 261.0 | 298.0 | 307.1 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 | 0 | 30 | 1 | 153.9 | 154 | 112.5 | 17.9 | 30.7 | 59.5 | 163.5 | 239.0 | 275.4 | 285.0 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97 | 0 | 88 | 1 | 186 | 186.5 | 106.1 | 32.6 | 54.2 | 111.0 | 208.0 | 263.0 | 300.4 | 308.4 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.406700 | 0.09689 | 0.21680 | 0.59660 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.502000 | 1.24200 | 1.81600 | |
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.192300 | 0.06460 | -0.31890 | -0.06565 |
| Hazard Ratio | 1 | 31 | 30 | 0.825100 | 0.72700 | 0.93650 | |
| Age at delivery | 27 | 31 | 4 | -0.092200 | 0.07947 | -0.24800 | 0.06357 |
| Hazard Ratio | 27 | 31 | 4 | 0.911900 | 0.78040 | 1.06600 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.071680 | 0.07413 | -0.07361 | 0.21700 |
| Hazard Ratio | 39 | 37 | -2 | 1.074000 | 0.92900 | 1.24200 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.005726 | 0.19320 | -0.38440 | 0.37300 | |
| Hazard Ratio | 2 | 1 | 0.994300 | 0.68080 | 1.45200 | ||
| Combined pain --- Yes:No | 1 | 2 | -0.235200 | 0.19800 | -0.62320 | 0.15290 | |
| Hazard Ratio | 1 | 2 | 0.790400 | 0.53620 | 1.16500 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.324700 | 0.18550 | -0.03882 | 0.68820 | |
| Hazard Ratio | 1 | 2 | 1.384000 | 0.96190 | 1.99000 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.355400 | 0.22380 | -0.08325 | 0.79410 | |
| Hazard Ratio | 1 | 2 | 1.427000 | 0.92010 | 2.21200 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.635600 | 0.20080 | 0.24200 | 1.02900 | |
| Hazard Ratio | 1 | 2 | 1.888000 | 1.27400 | 2.79900 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.001079 | 0.37710 | -0.74020 | 0.73810 | |
| Hazard Ratio | 1 | 2 | 0.998900 | 0.47700 | 2.09200 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 17.59 | 1 | <0.0001 |
| Total days supplied MOUD (method 3) | 8.85 | 1 | 0.0029 |
| Age at delivery | 1.35 | 1 | 0.2456 |
| Route of delivery | 0.00 | 1 | 0.9764 |
| Number of Gestation weeks | 0.94 | 1 | 0.3331 |
| Combined pain | 1.41 | 1 | 0.2350 |
| Alcohol or other substance use | 3.07 | 1 | 0.0800 |
| Benzodiazepine or anticonvulsant use | 2.52 | 1 | 0.1122 |
| Anxiety and depression combined | 10.01 | 1 | 0.0016 |
| Maternal morbidity | 0.00 | 1 | 0.9977 |
| TOTAL | 61.67 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.2263 | 0.06572 | -0.3551 | -0.09746 |
| Hazard Ratio | 1 | 31 | 30 | 0.7975 | 0.7011 | 0.90710 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Total days supplied MOUD (method 3) | 11.85 | 1 | 0.0006 |
| TOTAL | 11.85 | 1 | 0.0006 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.467700 | 0.09835 | 0.27490 | 0.66050 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.596000 | 1.31600 | 1.93600 | |
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.194100 | 0.06405 | -0.31960 | -0.06857 |
| Hazard Ratio | 1 | 31 | 30 | 0.823600 | 0.72640 | 0.93370 | |
| Age at delivery | 27 | 31 | 4 | -0.094170 | 0.07917 | -0.24930 | 0.06100 |
| Hazard Ratio | 27 | 31 | 4 | 0.910100 | 0.77930 | 1.06300 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.069940 | 0.07470 | -0.07647 | 0.21640 |
| Hazard Ratio | 39 | 37 | -2 | 1.072000 | 0.92640 | 1.24200 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.005208 | 0.19310 | -0.38360 | 0.37320 | |
| Hazard Ratio | 2 | 1 | 0.994800 | 0.68140 | 1.45200 | ||
| Combined pain --- Yes:No | 1 | 2 | -0.246600 | 0.19930 | -0.63730 | 0.14410 | |
| Hazard Ratio | 1 | 2 | 0.781400 | 0.52870 | 1.15500 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.325300 | 0.18570 | -0.03873 | 0.68940 | |
| Hazard Ratio | 1 | 2 | 1.384000 | 0.96200 | 1.99200 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.373200 | 0.22820 | -0.07416 | 0.82050 | |
| Hazard Ratio | 1 | 2 | 1.452000 | 0.92850 | 2.27200 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.640100 | 0.20040 | 0.24730 | 1.03300 | |
| Hazard Ratio | 1 | 2 | 1.897000 | 1.28100 | 2.80900 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.020030 | 0.37720 | -0.75930 | 0.71930 | |
| Hazard Ratio | 1 | 2 | 0.980200 | 0.46800 | 2.05300 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 25.25 | 2 | <0.0001 |
| Nonlinear | 1.17 | 1 | 0.2797 |
| Total days supplied MOUD (method 3) | 9.18 | 1 | 0.0024 |
| Age at delivery | 1.42 | 1 | 0.2338 |
| Route of delivery | 0.00 | 1 | 0.9785 |
| Number of Gestation weeks | 0.88 | 1 | 0.3486 |
| Combined pain | 1.53 | 1 | 0.2161 |
| Alcohol or other substance use | 3.07 | 1 | 0.0798 |
| Benzodiazepine or anticonvulsant use | 2.68 | 1 | 0.1019 |
| Anxiety and depression combined | 10.19 | 1 | 0.0014 |
| Maternal morbidity | 0.00 | 1 | 0.9576 |
| TOTAL | 71.22 | 11 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.41000 | 0.09798 | 0.21800 | 0.60200 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.50700 | 1.24400 | 1.82600 | |
| Total days supplied buprenorphine | 1 | 31 | 30 | -0.24020 | 0.06656 | -0.37070 | -0.10970 |
| Hazard Ratio | 1 | 31 | 30 | 0.78650 | 0.69030 | 0.89610 | |
| Age at delivery | 27 | 31 | 4 | -0.08383 | 0.07952 | -0.23970 | 0.07202 |
| Hazard Ratio | 27 | 31 | 4 | 0.91960 | 0.78690 | 1.07500 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.07175 | 0.07370 | -0.07269 | 0.21620 |
| Hazard Ratio | 39 | 37 | -2 | 1.07400 | 0.92990 | 1.24100 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.05152 | 0.19580 | -0.43520 | 0.33220 | |
| Hazard Ratio | 2 | 1 | 0.94980 | 0.64710 | 1.39400 | ||
| Combined pain --- Yes:No | 1 | 2 | -0.24090 | 0.19880 | -0.63040 | 0.14870 | |
| Hazard Ratio | 1 | 2 | 0.78590 | 0.53240 | 1.16000 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.38810 | 0.18630 | 0.02293 | 0.75330 | |
| Hazard Ratio | 1 | 2 | 1.47400 | 1.02300 | 2.12400 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.36220 | 0.22470 | -0.07817 | 0.80260 | |
| Hazard Ratio | 1 | 2 | 1.43700 | 0.92480 | 2.23100 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.65110 | 0.20130 | 0.25650 | 1.04600 | |
| Hazard Ratio | 1 | 2 | 1.91800 | 1.29200 | 2.84500 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.01000 | 0.37850 | -0.75180 | 0.73170 | |
| Hazard Ratio | 1 | 2 | 0.99000 | 0.47150 | 2.07900 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 17.48 | 1 | <0.0001 |
| Total days supplied buprenorphine | 13.01 | 1 | 0.0003 |
| Age at delivery | 1.11 | 1 | 0.2914 |
| Route of delivery | 0.07 | 1 | 0.7925 |
| Number of Gestation weeks | 0.95 | 1 | 0.3297 |
| Combined pain | 1.47 | 1 | 0.2257 |
| Alcohol or other substance use | 4.34 | 1 | 0.0372 |
| Benzodiazepine or anticonvulsant use | 2.60 | 1 | 0.1068 |
| Anxiety and depression combined | 10.44 | 1 | 0.0012 |
| Maternal morbidity | 0.00 | 1 | 0.9789 |
| TOTAL | 66.41 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied buprenorphine | 1 | 31 | 30 | -0.2751 | 0.06795 | -0.4082 | -0.1419 |
| Hazard Ratio | 1 | 31 | 30 | 0.7595 | 0.6648 | 0.8677 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Total days supplied buprenorphine | 16.37 | 1 | <0.0001 |
| TOTAL | 16.37 | 1 | <0.0001 |
| time | probability |
|---|---|
| 2 | 0.9988864 |
| 8 | 0.9977728 |
| 19 | 0.9966592 |
| 32 | 0.9955457 |
| 45 | 0.9944321 |
| 70 | 0.9933185 |
| 97 | 0.9922049 |
| 101 | 0.9910913 |
| 111 | 0.9899777 |
| 125 | 0.9888641 |
| 131 | 0.9877506 |
| 173 | 0.9866370 |
| 177 | 0.9855234 |
| 217 | 0.9844098 |
| 222 | 0.9832962 |
| 240 | 0.9821826 |
| 258 | 0.9810690 |
| 261 | 0.9799555 |
| 270 | 0.9788419 |
| 274 | 0.9777283 |
| 287 | 0.9766147 |
| 310 | 0.9755011 |
| 323 | 0.9755011 |
| 27 | 0.9984326 |
| 35 | 0.9968652 |
| 77 | 0.9952978 |
| 87 | 0.9937304 |
| 101 | 0.9921630 |
| 118 | 0.9905956 |
| 138 | 0.9890282 |
| 147 | 0.9874608 |
| 166 | 0.9858934 |
| 193 | 0.9843260 |
| 213 | 0.9827586 |
| 215 | 0.9811912 |
| 217 | 0.9796238 |
| 245 | 0.9780564 |
| 295 | 0.9764890 |
| 300 | 0.9749216 |
| 301 | 0.9733542 |
| 319 | 0.9717868 |
| 323 | 0.9717868 |
| 7 | 0.9998315 |
| 8 | 0.9996631 |
| 17 | 0.9994946 |
| 18 | 0.9993261 |
| 34 | 0.9991577 |
| 35 | 0.9989892 |
| 41 | 0.9988208 |
| 45 | 0.9986523 |
| 47 | 0.9984838 |
| 52 | 0.9983154 |
| 59 | 0.9979784 |
| 60 | 0.9978100 |
| 61 | 0.9976415 |
| 63 | 0.9974730 |
| 65 | 0.9973046 |
| 66 | 0.9971361 |
| 69 | 0.9969677 |
| 75 | 0.9967992 |
| 93 | 0.9966307 |
| 95 | 0.9964623 |
| 110 | 0.9962938 |
| 112 | 0.9961253 |
| 120 | 0.9959569 |
| 121 | 0.9957884 |
| 128 | 0.9956199 |
| 138 | 0.9954515 |
| 140 | 0.9952830 |
| 144 | 0.9951146 |
| 151 | 0.9947776 |
| 153 | 0.9946092 |
| 156 | 0.9942722 |
| 171 | 0.9941038 |
| 175 | 0.9939353 |
| 178 | 0.9937668 |
| 181 | 0.9935984 |
| 182 | 0.9934299 |
| 184 | 0.9932615 |
| 185 | 0.9930930 |
| 188 | 0.9927561 |
| 204 | 0.9925876 |
| 208 | 0.9924191 |
| 211 | 0.9922507 |
| 216 | 0.9920822 |
| 220 | 0.9919137 |
| 223 | 0.9917453 |
| 228 | 0.9914084 |
| 229 | 0.9912399 |
| 233 | 0.9910714 |
| 235 | 0.9909030 |
| 236 | 0.9907345 |
| 239 | 0.9905660 |
| 240 | 0.9903976 |
| 246 | 0.9900606 |
| 247 | 0.9898922 |
| 250 | 0.9897237 |
| 253 | 0.9895553 |
| 254 | 0.9893868 |
| 261 | 0.9892183 |
| 262 | 0.9890499 |
| 263 | 0.9888814 |
| 265 | 0.9887129 |
| 267 | 0.9885445 |
| 268 | 0.9883760 |
| 271 | 0.9882075 |
| 274 | 0.9880391 |
| 275 | 0.9878706 |
| 279 | 0.9877022 |
| 287 | 0.9875337 |
| 289 | 0.9873652 |
| 290 | 0.9871968 |
| 296 | 0.9870283 |
| 298 | 0.9866914 |
| 302 | 0.9865229 |
| 304 | 0.9863544 |
| 305 | 0.9861860 |
| 308 | 0.9858491 |
| 310 | 0.9856806 |
| 313 | 0.9855121 |
| 316 | 0.9853437 |
| 323 | 0.9853437 |
Call:
survdiff(formula = Surv(days.to.event, outcome.bin) ~ moud.both3div,
data = moud)
N Observed Expected (O-E)^2/E (O-E)^2/V
moud.both3div=Only pre 898 22 15.2 3.06 3.48
moud.both3div=Only post 638 18 10.8 4.83 5.28
moud.both3div=Both pre and post 5936 87 101.0 1.95 9.54
Chisq= 9.8 on 2 degrees of freedom, p= 0.007
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.142500 | 0.09738 | -0.33340 | 0.04834 |
| Hazard Ratio | 1 | 31 | 30 | 0.867200 | 0.71650 | 1.05000 | |
| Year of delivery | 2016 | 2018 | 2 | 0.405800 | 0.09657 | 0.21660 | 0.59510 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.501000 | 1.24200 | 1.81300 | |
| Age at delivery | 27 | 31 | 4 | -0.095060 | 0.07930 | -0.25050 | 0.06038 |
| Hazard Ratio | 27 | 31 | 4 | 0.909300 | 0.77840 | 1.06200 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.069880 | 0.07310 | -0.07339 | 0.21310 |
| Hazard Ratio | 39 | 37 | -2 | 1.072000 | 0.92920 | 1.23800 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | 0.198600 | 0.31710 | -0.42290 | 0.82000 | |
| Hazard Ratio | 3 | 1 | 1.220000 | 0.65510 | 2.27100 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.205500 | 0.34720 | -0.47500 | 0.88610 | |
| Hazard Ratio | 3 | 2 | 1.228000 | 0.62190 | 2.42600 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.008465 | 0.19370 | -0.38800 | 0.37110 | |
| Hazard Ratio | 2 | 1 | 0.991600 | 0.67840 | 1.44900 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.233900 | 0.19810 | -0.15450 | 0.62220 | |
| Hazard Ratio | 2 | 1 | 1.263000 | 0.85690 | 1.86300 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.328700 | 0.18510 | -0.03412 | 0.69160 | |
| Hazard Ratio | 1 | 2 | 1.389000 | 0.96650 | 1.99700 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.355500 | 0.22380 | -0.08322 | 0.79410 | |
| Hazard Ratio | 1 | 2 | 1.427000 | 0.92010 | 2.21300 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.637800 | 0.19940 | 0.24710 | 1.02900 | |
| Hazard Ratio | 1 | 2 | 1.892000 | 1.28000 | 2.79700 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.007480 | 0.37660 | -0.74570 | 0.73070 | |
| Hazard Ratio | 1 | 2 | 0.992500 | 0.47440 | 2.07700 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 0.48 | 2 | 0.7870 |
| Total days supplied MOUD (method 3) | 2.14 | 1 | 0.1432 |
| Year of delivery | 17.64 | 1 | <0.0001 |
| Age at delivery | 1.44 | 1 | 0.2302 |
| Route of delivery | 0.00 | 1 | 0.9652 |
| Number of Gestation weeks | 0.92 | 1 | 0.3385 |
| Combined pain | 1.39 | 1 | 0.2380 |
| Alcohol or other substance use | 3.15 | 1 | 0.0757 |
| Benzodiazepine or anticonvulsant use | 2.52 | 1 | 0.1121 |
| Anxiety and depression combined | 10.23 | 1 | 0.0014 |
| Maternal morbidity | 0.00 | 1 | 0.9841 |
| TOTAL | 64.13 | 12 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.40600 | 0.09581 | 0.218300 | 0.59380 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.50100 | 1.244000 | 1.81100 | |
| Age at delivery | 27 | 31 | 4 | -0.10250 | 0.08031 | -0.259900 | 0.05489 |
| Hazard Ratio | 27 | 31 | 4 | 0.90260 | 0.771100 | 1.05600 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.07466 | 0.07228 | -0.067000 | 0.21630 |
| Hazard Ratio | 39 | 37 | -2 | 1.07800 | 0.935200 | 1.24200 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | 0.47820 | 0.23970 | 0.008477 | 0.94790 | |
| Hazard Ratio | 3 | 1 | 1.61300 | 1.009000 | 2.58000 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.55420 | 0.25520 | 0.054010 | 1.05400 | |
| Hazard Ratio | 3 | 2 | 1.74100 | 1.055000 | 2.87000 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.02199 | 0.19260 | -0.399500 | 0.35560 | |
| Hazard Ratio | 2 | 1 | 0.97830 | 0.670600 | 1.42700 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.23320 | 0.19820 | -0.155300 | 0.62160 | |
| Hazard Ratio | 2 | 1 | 1.26300 | 0.856200 | 1.86200 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.35440 | 0.18430 | -0.006726 | 0.71560 | |
| Hazard Ratio | 1 | 2 | 1.42500 | 0.993300 | 2.04500 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.35410 | 0.22380 | -0.084660 | 0.79280 | |
| Hazard Ratio | 1 | 2 | 1.42500 | 0.918800 | 2.21000 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.63990 | 0.19910 | 0.249800 | 1.03000 | |
| Hazard Ratio | 1 | 2 | 1.89600 | 1.284000 | 2.80100 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.01368 | 0.37620 | -0.751000 | 0.72370 | |
| Hazard Ratio | 1 | 2 | 0.98640 | 0.471900 | 2.06200 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 7.27 | 2 | 0.0264 |
| Year of delivery | 17.94 | 1 | <0.0001 |
| Age at delivery | 1.63 | 1 | 0.2013 |
| Route of delivery | 0.01 | 1 | 0.9092 |
| Number of Gestation weeks | 1.07 | 1 | 0.3010 |
| Combined pain | 1.38 | 1 | 0.2394 |
| Alcohol or other substance use | 3.70 | 1 | 0.0544 |
| Benzodiazepine or anticonvulsant use | 2.50 | 1 | 0.1136 |
| Anxiety and depression combined | 10.33 | 1 | 0.0013 |
| Maternal morbidity | 0.00 | 1 | 0.9710 |
| TOTAL | 61.12 | 11 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied buprenorphine | 1 | 31 | 30 | -0.17740 | 0.10010 | -0.37370 | 0.01879 |
| Hazard Ratio | 1 | 31 | 30 | 0.83740 | 0.68820 | 1.01900 | |
| Year of delivery | 2014 | 2018 | 4 | 0.81690 | 0.19360 | 0.43750 | 1.19600 |
| Hazard Ratio | 2014 | 2018 | 4 | 2.26300 | 1.54900 | 3.30800 | |
| Age at delivery | 25 | 35 | 10 | -0.21850 | 0.19860 | -0.60770 | 0.17070 |
| Hazard Ratio | 25 | 35 | 10 | 0.80370 | 0.54460 | 1.18600 | |
| Number of Gestation weeks | 37 | 39 | 2 | -0.06631 | 0.07196 | -0.20740 | 0.07473 |
| Hazard Ratio | 37 | 39 | 2 | 0.93580 | 0.81270 | 1.07800 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | 0.17510 | 0.32130 | -0.45470 | 0.80500 | |
| Hazard Ratio | 3 | 1 | 1.19100 | 0.63470 | 2.23700 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.34510 | 0.35100 | -0.34290 | 1.03300 | |
| Hazard Ratio | 3 | 2 | 1.41200 | 0.70970 | 2.81000 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.05573 | 0.19610 | -0.44000 | 0.32860 | |
| Hazard Ratio | 2 | 1 | 0.94580 | 0.64400 | 1.38900 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.23430 | 0.19910 | -0.15600 | 0.62460 | |
| Hazard Ratio | 2 | 1 | 1.26400 | 0.85550 | 1.86800 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.40080 | 0.18590 | 0.03634 | 0.76530 | |
| Hazard Ratio | 1 | 2 | 1.49300 | 1.03700 | 2.15000 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.36230 | 0.22480 | -0.07839 | 0.80300 | |
| Hazard Ratio | 1 | 2 | 1.43700 | 0.92460 | 2.23200 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.65390 | 0.20040 | 0.26120 | 1.04700 | |
| Hazard Ratio | 1 | 2 | 1.92300 | 1.29800 | 2.84800 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.02123 | 0.37770 | -0.76150 | 0.71910 | |
| Hazard Ratio | 1 | 2 | 0.97900 | 0.46690 | 2.05300 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 0.97 | 2 | 0.6157 |
| Total days supplied buprenorphine | 3.14 | 1 | 0.0763 |
| Year of delivery | 17.78 | 1 | <0.0001 |
| Age at delivery | 1.21 | 1 | 0.2709 |
| Route of delivery | 0.08 | 1 | 0.7764 |
| Number of Gestation weeks | 0.85 | 1 | 0.3561 |
| Combined pain | 1.38 | 1 | 0.2395 |
| Alcohol or other substance use | 4.65 | 1 | 0.0311 |
| Benzodiazepine or anticonvulsant use | 2.60 | 1 | 0.1070 |
| Anxiety and depression combined | 10.64 | 1 | 0.0011 |
| Maternal morbidity | 0.00 | 1 | 0.9551 |
| TOTAL | 70.28 | 12 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2014 | 2018 | 4 | 0.81930 | 0.19160 | 0.44380 | 1.19500 |
| Hazard Ratio | 2014 | 2018 | 4 | 2.26900 | 1.55900 | 3.30300 | |
| Age at delivery | 25 | 35 | 10 | -0.24100 | 0.20120 | -0.63530 | 0.15330 |
| Hazard Ratio | 25 | 35 | 10 | 0.78590 | 0.52980 | 1.16600 | |
| Number of Gestation weeks | 37 | 39 | 2 | -0.07246 | 0.07101 | -0.21160 | 0.06673 |
| Hazard Ratio | 37 | 39 | 2 | 0.93010 | 0.80930 | 1.06900 | |
| MOUD receipt timing --- Only pre:Both pre and post | 3 | 1 | 0.52130 | 0.24070 | 0.04942 | 0.99310 | |
| Hazard Ratio | 3 | 1 | 1.68400 | 1.05100 | 2.70000 | ||
| MOUD receipt timing --- Only post:Both pre and post | 3 | 2 | 0.77540 | 0.25690 | 0.27180 | 1.27900 | |
| Hazard Ratio | 3 | 2 | 2.17200 | 1.31200 | 3.59300 | ||
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.07435 | 0.19530 | -0.45710 | 0.30840 | |
| Hazard Ratio | 2 | 1 | 0.92830 | 0.63310 | 1.36100 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.23410 | 0.19920 | -0.15640 | 0.62460 | |
| Hazard Ratio | 2 | 1 | 1.26400 | 0.85520 | 1.86800 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.43350 | 0.18580 | 0.06937 | 0.79770 | |
| Hazard Ratio | 1 | 2 | 1.54300 | 1.07200 | 2.22000 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.36170 | 0.22480 | -0.07900 | 0.80230 | |
| Hazard Ratio | 1 | 2 | 1.43600 | 0.92400 | 2.23100 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.65680 | 0.20000 | 0.26490 | 1.04900 | |
| Hazard Ratio | 1 | 2 | 1.92900 | 1.30300 | 2.85400 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.02996 | 0.37720 | -0.76920 | 0.70930 | |
| Hazard Ratio | 1 | 2 | 0.97050 | 0.46340 | 2.03300 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD receipt timing | 11.65 | 2 | 0.0029 |
| Year of delivery | 18.27 | 1 | <0.0001 |
| Age at delivery | 1.44 | 1 | 0.2307 |
| Route of delivery | 0.14 | 1 | 0.7035 |
| Number of Gestation weeks | 1.04 | 1 | 0.3068 |
| Combined pain | 1.38 | 1 | 0.2402 |
| Alcohol or other substance use | 5.45 | 1 | 0.0196 |
| Benzodiazepine or anticonvulsant use | 2.59 | 1 | 0.1076 |
| Anxiety and depression combined | 10.78 | 1 | 0.0010 |
| Maternal morbidity | 0.01 | 1 | 0.9366 |
| TOTAL | 67.10 | 11 | <0.0001 |
| N | Overall | |
|---|---|---|
| (N=5728) | ||
| Year of delivery | 5728 (100.00) | |
| Median (interquartile range) | 2015 (2014—2017) | |
| Range | 2007—2018 | |
| Age at delivery | 5728 (100.00) | |
| Median (interquartile range) | 27 (24—30) | |
| Range | 17—44 | |
| Number of Gestation weeks | 5728 (100.00) | |
| Median (interquartile range) | 39 (37—39) | |
| Range | 21—42 | |
| Race | 5728 (100.00) | |
| American Indian or Alaska Native | 18/5728 (0.31) | |
| Asian or Pacific Islander | 8/5728 (0.14) | |
| Black of African American | 140/5728 (2.44) | |
| Other or Unknown | 41/5728 (0.72) | |
| White | 5521/5728 (96.39) | |
| Hispanic : Not Hispanic | 5721 (99.88) | 5675/5721 (99.20) |
| Race/Ethnicity combined | 5728 (100.00) | |
| Hispanic | 46/5728 (0.80) | |
| Non-Hispanic Asian | 8/5728 (0.14) | |
| Non-Hispanic Black | 139/5728 (2.43) | |
| Non-Hispanic Other | 45/5728 (0.79) | |
| Non-Hispanic White | 5490/5728 (95.84) | |
| Route of delivery : Vaginal | 5728 (100.00) | 3744/5728 (65.36) |
| Number of previous pregnancies | 5596 (97.70) | |
| Median (interquartile range) | 2 (1—3) | |
| Range | 0—23 | |
| Final outcome | 5728 (100.00) | |
| Death | 20/5728 (0.35) | |
| Overdose | 56/5728 (0.98) | |
| Loss of enrollment | 671/5728 (11.71) | |
| Censored | 4981/5728 (86.96) | |
| Final outcome (w/o all payer data) | 5728 (100.00) | |
| Death | 8/5728 (0.14) | |
| Overdose | 51/5728 (0.89) | |
| Loss of enrollment | 688/5728 (12.01) | |
| Censored | 4981/5728 (86.96) | |
| Total days supplied MOUD | 5728 (100.00) | |
| Median (interquartile range) | 93 (56—120) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery | 5728 (100.00) | |
| Median (interquartile range) | 74 (36—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery | 5728 (100.00) | |
| Median (interquartile range) | 29 (7—41) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 2) | 5728 (100.00) | |
| Median (interquartile range) | 98 (56—122) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 2) | 5728 (100.00) | |
| Median (interquartile range) | 74 (36—90) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 2) | 5728 (100.00) | |
| Median (interquartile range) | 30 (12—42) | |
| Range | 0—42 | |
| Total days supplied MOUD (method 3) | 5728 (100.00) | |
| Median (interquartile range) | 88 (49—110) | |
| Range | 1—132 | |
| Total days supplied MOUD before delivery (method 3) | 5728 (100.00) | |
| Median (interquartile range) | 62 (30—77) | |
| Range | 0—90 | |
| Total days supplied MOUD after delivery (method 3) | 5728 (100.00) | |
| Median (interquartile range) | 30 (13—40) | |
| Range | 0—42 | |
| Avg dose pre-delivery (mg) | 5669 (98.97) | |
| Median (interquartile range) | 14.55 (8.00—16.00) | |
| Range | 0.00—50.00 | |
| Avg dose post-delivery (mg) | 5669 (98.97) | |
| Median (interquartile range) | 9.21 (4.00—16.00) | |
| Range | 0.00—53.57 | |
| Avg dose exposure (mg) | 5669 (98.97) | |
| Median (interquartile range) | 14.22 (9.94—16.00) | |
| Range | 0.14—53.57 | |
| Total days buprenorphine before delivery (method 3) | 5621 (98.13) | |
| Median (interquartile range) | 62.00 (30.00—77.00) | |
| Range | 0.00—90.00 | |
| Total days buprenorphine after delivery (method 3) | 5621 (98.13) | |
| Median (interquartile range) | 30.00 (13.00—40.00) | |
| Range | 0.00—42.00 | |
| Total days supplied buprenorphine | 5621 (98.13) | |
| Median (interquartile range) | 89.00 (50.00—111.00) | |
| Range | 1.00—132.00 | |
| Avg dose BUP pre-delivery (mg) | 5621 (98.13) | |
| Median (interquartile range) | 14.49 (8.00—16.00) | |
| Range | 0.00—35.42 | |
| Avg dose BUP post-delivery (mg) | 5621 (98.13) | |
| Median (interquartile range) | 9.14 (4.00—16.00) | |
| Range | 0.00—42.67 | |
| Avg dose BUP exposure (mg) | 5621 (98.13) | |
| Median (interquartile range) | 14.15 (9.79—16.00) | |
| Range | 0.14—42.67 | |
| Combined pain : Yes | 5728 (100.00) | 4537/5728 (79.21) |
| Schizophrenia or personality disorder : Yes | 5728 (100.00) | 426/5728 (7.44) |
| Alcohol or other substance use : Yes | 5728 (100.00) | 2704/5728 (47.21) |
| Benzodiazepine or anticonvulsant use : Yes | 5728 (100.00) | 906/5728 (15.82) |
| Maternal morbidity : Yes | 5728 (100.00) | 470/5728 (8.21) |
| Anxiety and depression combined : Yes | 5728 (100.00) | 2542/5728 (44.38) |
| Back pain : Yes | 5728 (100.00) | 2388/5728 (41.69) |
| Depression : Yes | 5728 (100.00) | 2173/5728 (37.94) |
| Bipolar disorder : Yes | 5728 (100.00) | 618/5728 (10.79) |
| Other substance use : Yes | 5728 (100.00) | 2582/5728 (45.08) |
| Tobacco use : Yes | 5728 (100.00) | 4105/5728 (71.67) |
| Med NSAIDS : Yes | 5728 (100.00) | 3468/5728 (60.54) |
| Schizophrenia psychotic disorders : Yes | 5728 (100.00) | 318/5728 (5.55) |
| Anxiety : Yes | 5728 (100.00) | 1048/5728 (18.30) |
| Med benzodiazepine use : Yes | 5728 (100.00) | 599/5728 (10.46) |
| Maternal morbidity : Yes | 5728 (100.00) | 470/5728 (8.21) |
| Dental pain : Yes | 5728 (100.00) | 229/5728 (4.00) |
| Alcohol use disorder : Yes | 5728 (100.00) | 410/5728 (7.16) |
| Med anticonvulsant use : Yes | 5728 (100.00) | 367/5728 (6.41) |
| Med muscle relaxant use : Yes | 5728 (100.00) | 280/5728 (4.89) |
| Personality disorder : Yes | 5728 (100.00) | 183/5728 (3.19) |
| Fibromyalgia : Yes | 5728 (100.00) | 303/5728 (5.29) |
| CDC SVI overall percentile ranking of all 4 themes | 5363 (93.63) | |
| Median (interquartile range) | 0.57 (0.36—0.79) | |
| Range | 0.00—1.00 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76 | 0 | 72 | 1 | 187.1 | 190 | 106.9 | 18.75 | 46.00 | 123.75 | 210.50 | 268.50 | 299.50 | 308.50 |
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 0 | 20 | 1 | 165.2 | 163.5 | 118.4 | 18.15 | 33.40 | 58.75 | 174.50 | 262.50 | 280.10 | 290.90 |
Value 2 19 35 45 52 61 128 140 156 171 178 181 217 240
Frequency 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Proportion 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Value 261 267 275 279 290 308
Frequency 1 1 1 1 1 1
Proportion 0.05 0.05 0.05 0.05 0.05 0.05
For the frequency table, variable is rounded to the nearest 0
| n | missing | distinct | Info | Mean | pMedian | Gmd | .05 | .10 | .25 | .50 | .75 | .90 | .95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56 | 0 | 54 | 1 | 195 | 199.8 | 103 | 24.75 | 64.50 | 129.50 | 216.00 | 270.25 | 301.50 | 310.00 |
Call: survfit(formula = Surv(days.to.event, outcome.bin) ~ 1, data = moud18)
n events median 0.95LCL 0.95UCL
[1,] 5728 76 NA NA NA
Min. 1st Qu. Median Mean 3rd Qu. Max.
2.0 120.0 208.0 186.9 270.0 323.0
| time | probability |
|---|---|
| 2 | 0.9998254 |
| 7 | 0.9996508 |
| 8 | 0.9994763 |
| 18 | 0.9993017 |
| 19 | 0.9991271 |
| 27 | 0.9989525 |
| 35 | 0.9987779 |
| 45 | 0.9986034 |
| 47 | 0.9984288 |
| 52 | 0.9982542 |
| 61 | 0.9980796 |
| 63 | 0.9979050 |
| 66 | 0.9977304 |
| 69 | 0.9975559 |
| 97 | 0.9973813 |
| 110 | 0.9972067 |
| 111 | 0.9970321 |
| 112 | 0.9968575 |
| 120 | 0.9966830 |
| 125 | 0.9965084 |
| 128 | 0.9963338 |
| 131 | 0.9961592 |
| 138 | 0.9958101 |
| 140 | 0.9956355 |
| 144 | 0.9954609 |
| 147 | 0.9952863 |
| 156 | 0.9951117 |
| 166 | 0.9949372 |
| 171 | 0.9947626 |
| 175 | 0.9945880 |
| 177 | 0.9944134 |
| 178 | 0.9942388 |
| 181 | 0.9940642 |
| 182 | 0.9938897 |
| 184 | 0.9937151 |
| 188 | 0.9935405 |
| 208 | 0.9933659 |
| 213 | 0.9931913 |
| 215 | 0.9930168 |
| 217 | 0.9926676 |
| 220 | 0.9924930 |
| 222 | 0.9923184 |
| 223 | 0.9921439 |
| 228 | 0.9919693 |
| 229 | 0.9917947 |
| 235 | 0.9916201 |
| 239 | 0.9914455 |
| 240 | 0.9910964 |
| 246 | 0.9909218 |
| 258 | 0.9907472 |
| 261 | 0.9905726 |
| 265 | 0.9903980 |
| 267 | 0.9902235 |
| 268 | 0.9900489 |
| 270 | 0.9898743 |
| 271 | 0.9896997 |
| 274 | 0.9895251 |
| 275 | 0.9893506 |
| 279 | 0.9891760 |
| 287 | 0.9890014 |
| 289 | 0.9888268 |
| 290 | 0.9886522 |
| 295 | 0.9884777 |
| 296 | 0.9883031 |
| 298 | 0.9881285 |
| 301 | 0.9879539 |
| 302 | 0.9877793 |
| 304 | 0.9876047 |
| 308 | 0.9874302 |
| 310 | 0.9870810 |
| 316 | 0.9869064 |
| 319 | 0.9867318 |
| 323 | 0.9867318 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.32390 | 0.15410 | 0.02183 | 0.6260 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.38300 | 1.02200 | 1.8700 | |
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.26840 | 0.08350 | -0.43200 | -0.1047 |
| Hazard Ratio | 1 | 31 | 30 | 0.76460 | 0.64920 | 0.9006 | |
| Age at delivery | 27 | 31 | 4 | -0.04082 | 0.10860 | -0.25370 | 0.1721 |
| Hazard Ratio | 27 | 31 | 4 | 0.96000 | 0.77590 | 1.1880 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.09981 | 0.09263 | -0.08174 | 0.2814 |
| Hazard Ratio | 39 | 37 | -2 | 1.10500 | 0.92150 | 1.3250 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | 0.18350 | 0.24580 | -0.29820 | 0.6652 | |
| Hazard Ratio | 2 | 1 | 1.20100 | 0.74220 | 1.9450 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.26780 | 0.27150 | -0.26430 | 0.8000 | |
| Hazard Ratio | 2 | 1 | 1.30700 | 0.76780 | 2.2250 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.06777 | 0.23750 | -0.39760 | 0.5332 | |
| Hazard Ratio | 1 | 2 | 1.07000 | 0.67190 | 1.7040 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.22720 | 0.28610 | -0.33350 | 0.7879 | |
| Hazard Ratio | 1 | 2 | 1.25500 | 0.71640 | 2.1990 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.74930 | 0.25280 | 0.25380 | 1.2450 | |
| Hazard Ratio | 1 | 2 | 2.11600 | 1.28900 | 3.4720 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.15200 | 0.46710 | -1.06800 | 0.7636 | |
| Hazard Ratio | 1 | 2 | 0.85900 | 0.34380 | 2.1460 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 4.41 | 1 | 0.0358 |
| Total days supplied MOUD (method 3) | 10.33 | 1 | 0.0013 |
| Age at delivery | 0.14 | 1 | 0.7069 |
| Route of delivery | 0.56 | 1 | 0.4553 |
| Number of Gestation weeks | 1.16 | 1 | 0.2809 |
| Combined pain | 0.97 | 1 | 0.3239 |
| Alcohol or other substance use | 0.08 | 1 | 0.7752 |
| Benzodiazepine or anticonvulsant use | 0.63 | 1 | 0.4268 |
| Anxiety and depression combined | 8.78 | 1 | 0.0030 |
| Maternal morbidity | 0.11 | 1 | 0.7449 |
| TOTAL | 39.60 | 10 | <0.0001 |
`
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Total days supplied MOUD (method 3) | 1 | 31 | 30 | -0.293 | 0.08475 | -0.4591 | -0.1269 |
| Hazard Ratio | 1 | 31 | 30 | 0.746 | 0.6318 | 0.8808 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Total days supplied MOUD (method 3) | 11.95 | 1 | 0.0005 |
| TOTAL | 11.95 | 1 | 0.0005 |
| N | Overall | |
|---|---|---|
| (N=7472) | ||
| Total days supplied MOUD (method 3) | 7472 (100.00) | |
| Median (interquartile range) | 89 (47—112) | |
| Range | 1—132 | |
| MOUD days exposure shifted approach | 7472 (100.00) | |
| Median (interquartile range) | 92 (50—115) | |
| Range | 1—132 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| Year of delivery | 2016 | 2018 | 2 | 0.407700 | 0.09674 | 0.21810 | 0.59740 |
| Hazard Ratio | 2016 | 2018 | 2 | 1.503000 | 1.24400 | 1.81700 | |
| MOUD days exposure shifted approach | 1 | 31 | 30 | -0.181000 | 0.06375 | -0.30600 | -0.05608 |
| Hazard Ratio | 1 | 31 | 30 | 0.834400 | 0.73640 | 0.94550 | |
| Age at delivery | 27 | 31 | 4 | -0.092560 | 0.07950 | -0.24840 | 0.06326 |
| Hazard Ratio | 27 | 31 | 4 | 0.911600 | 0.78010 | 1.06500 | |
| Number of Gestation weeks | 39 | 37 | -2 | 0.072490 | 0.07386 | -0.07227 | 0.21720 |
| Hazard Ratio | 39 | 37 | -2 | 1.075000 | 0.93030 | 1.24300 | |
| Route of delivery --- Cesarean:Vaginal | 2 | 1 | -0.007594 | 0.19320 | -0.38620 | 0.37100 | |
| Hazard Ratio | 2 | 1 | 0.992400 | 0.67960 | 1.44900 | ||
| Combined pain --- No:Yes | 2 | 1 | 0.233600 | 0.19800 | -0.15430 | 0.62160 | |
| Hazard Ratio | 2 | 1 | 1.263000 | 0.85700 | 1.86200 | ||
| Alcohol or other substance use --- Yes:No | 1 | 2 | 0.331500 | 0.18540 | -0.03190 | 0.69490 | |
| Hazard Ratio | 1 | 2 | 1.393000 | 0.96860 | 2.00400 | ||
| Benzodiazepine or anticonvulsant use --- Yes:No | 1 | 2 | 0.354000 | 0.22390 | -0.08485 | 0.79290 | |
| Hazard Ratio | 1 | 2 | 1.425000 | 0.91870 | 2.21000 | ||
| Anxiety and depression combined --- Yes:No | 1 | 2 | 0.637700 | 0.20080 | 0.24420 | 1.03100 | |
| Hazard Ratio | 1 | 2 | 1.892000 | 1.27700 | 2.80500 | ||
| Maternal morbidity --- Yes:No | 1 | 2 | -0.001804 | 0.37690 | -0.74050 | 0.73690 | |
| Hazard Ratio | 1 | 2 | 0.998200 | 0.47690 | 2.08900 | ||
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| Year of delivery | 17.74 | 1 | <0.0001 |
| MOUD days exposure shifted approach | 8.06 | 1 | 0.0045 |
| Age at delivery | 1.36 | 1 | 0.2439 |
| Route of delivery | 0.00 | 1 | 0.9687 |
| Number of Gestation weeks | 0.97 | 1 | 0.3259 |
| Combined pain | 1.39 | 1 | 0.2380 |
| Alcohol or other substance use | 3.20 | 1 | 0.0738 |
| Benzodiazepine or anticonvulsant use | 2.50 | 1 | 0.1137 |
| Anxiety and depression combined | 10.08 | 1 | 0.0015 |
| Maternal morbidity | 0.00 | 1 | 0.9962 |
| TOTAL | 61.20 | 10 | <0.0001 |
Effects Response: Surv(days.to.event, outcome.bin) | |||||||
| Low | High | Δ | Effect | S.E. | Lower 0.95 | Upper 0.95 | |
|---|---|---|---|---|---|---|---|
| MOUD days exposure shifted approach | 1 | 31 | 30 | -0.2115 | 0.06532 | -0.3395 | -0.08345 |
| Hazard Ratio | 1 | 31 | 30 | 0.8094 | 0.7121 | 0.91990 | |
Wald Statistics for Surv(days.to.event, outcome.bin) | |||
| χ2 | d.f. | P | |
|---|---|---|---|
| MOUD days exposure shifted approach | 10.47 | 1 | 0.0012 |
| TOTAL | 10.47 | 1 | 0.0012 |
–> –> –> –> –> –> –> –>